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ABSTRACT
Amiodarone-Induced Pulmonary Toxicity in F344 Rats.
Michael D. Taylor
Amiodarone (AD) is gaining support as a first-line antiarrhythmic drug despite its
potentially fatal pulmonary toxicity involving inflammation and fibrosis.  The goals of
this study were to develop and characterize a rat model of amiodarone-induced
pulmonary toxicity (AIPT).   A protocol was developed in which male F344 rats were
instilled intratracheally (i.t.) with AD (6.25 mg/kg with a 3.125 mg/ml solution) in sterile
water or the sterile water vehicle on days 0 and 2, a protocol that led to the development
of pulmonary fibrosis on day 28 in the AD-treated animals.  Bronchoalveolar lavage
(BAL) resulted in the increased recovery of alveolar macrophages, neutrophils, and
eosinophils from i.t. AD-treated rats.  The BAL cells recovered from AD-treated rats at
day 3 produced more integrated phorbol-myristate-acetate stimulated luminol-dependent
chemiluminescence over 20 minutes than BAL cells from control rats. These findings
indicate that this model exhibits a transient pulmonary inflammation, with the potential
for elevated oxidant production in the lungs, and subsequent pulmonary fibrosis.  Also,
serum levels of surfactant protein-D, a protein normally found in the lungs, was elevated
in the serum of i.t. AD-treated rats, and is proposed as a biomarker for the toxicity.
However, attempts to elucidate the cytokine signaling behind the inflammatory events
were unsuccessful.  It was discovered that AD instillation produces a rapid and massive
damage to the alveolar-capillary barrier, and cellular death or damage to lung airway and
parenchymal cells.  This pathology is not consistent with that found in human AIPT.  AD
in solution was found to be at least partly in the form of a free radical, and capable of
generating hydroxyl radicals.  An attempt to modulate the toxicity of i.t. AD by
incorporating water-soluble antioxidants in the drug solution was unsuccessful, and might
have exacerbated the condition.  No consistent evidence for deiodination of AD in
solution was found, leaving the mechanism and significance of free radical generation by
AD undetermined.
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1Introduction
Figure 1: The structure of amiodarone.
Amiodarone (AD; 2-butyl-3-[3′,5′-diiodo-4′-α-diethylaminoethoxybenzoyl]-
benzofuran), an iodinated benzofuran derivative (Figure 1), is a very effective class III
antiarrhythmic drug.  It prolongs myocardial refractory period without altering membrane
potential.  AD inhibits ventricular tachycardia and ventricular premature beats as well as
ventricular fibrillation (Mason, 1987).  AD is a synthetic derivative of khellin, a chemical
extracted from a wild herbaceous Egyptian plant known as Umbelliferae.  Extract of
Umbelliferae had a reputation in folk medicine as a diuretic that could relieve renal colic,
or spasmodic pains usually associated with a calculus blockage of the ureter or urethra.  It
was in Cairo in 1930 where a technician of Anrep, a professor of pharmacology, self-
medicated his renal colic with khellin, and serendipitously found his angina disappeared
(Sneader, 1996).  AD was originally developed in the early 1960s in Belgium when
analogs of khellin were first systematically produced and studied. AD was found to be a
coronary vasodilator and used for the treatment of angina, but was withdrawn from the
market in 1967 due to reports of corneal deposits, skin photosensitivity, and thyroid
disorders (Sneader, 1996).  Despite this, AD was soon found to have unique
antiarrhythmic properties that, along with sotalol, formed the basis of the class III
classification (Singh, 1971).  Soon after this discovery, Argentinean cardiologist
2Mauricio Rosenbaum began using AD to effectively treat patients with various types of
arrhythmias and supraventricular tachycardias (Rosenbaum et al., 1974; Rosenbaum et
al., 1976).  AD was then introduced in the U.S. as an investigational antiarrhythmic drug
in 1978 and as such was not subjected to large, controlled, multicenter clinical trials
(Akoun et al., 1991).   Soon after, the first reports of AD-induced pulmonary toxicity
(AIPT), including pneumonitis and fibrosis, began to appear (Rotmensch et al., 1980).
However, because of the numerous reports of its clinical effectiveness, and despite its
known toxicity profile, AD was approved by the Food and Drug Administration in 1986
for use in the U.S.  It has been noted that AD did not undergo the structured drug
approval process and was actually approved on the basis of clinical experience rather
than rigorous study (Winkle, 1985).
When first accepted, its use was primarily as a drug of last resort in situations
where the severity of the arrhythmia outweighed the potential for side effects.  Also,
certain ventricular tachyarrhythmias are resistant to other treatments and respond only to
AD (Singh et al., 1989; Gill et al., 1992).  However, its effectiveness against various
types of arrhythmias as well as an increasing trend in clinical acceptance (Bauman, 1997)
has led to AD being the most frequently prescribed antiarrhythmic drug in 1998, with
about 1.65 million total patients (Connolly, 1999).  With arrhythmias accounting for
approximately 20% of all deaths in the U.S., an estimated 4.3 million deaths in 1996
alone (American Heart Association), there is a potential for AD use to continue to grow.
As the use of AD increases, the occurrence of its side effects will likely increase
accordingly.
3While AD produces several side effects, including corneal microdeposits,
bradycardia, skin photosensitivity, and altered thyroid function, pulmonary toxicity is one
of the most severe and potentially life-threatening (Mason, 1987; Martin and Rosenow,
1988a; Martin and Rosenow, 1988b).  AIPT occurs in 10 to 17% of patients taking AD
orally, and proves fatal in an estimated 5 to10% of affected patients (Pitcher, 1992).
AIPT is manifested in humans in several ways, including phospholipidosis, pneumonitis,
and fibrosis.
Phospholipidosis is an abnormal accumulation of phospholipid material in
alveolar macrophages and lung parenchymal cells, and is caused by AD and some other
cationic amphiphilic drugs (Akoun et al., 1986).  The storage of this phospholipid
material results in the formation of lysosomal lamellar inclusion bodies.  In the lungs, the
pulmonary macrophage is the cell type most affected (Akoun et al., 1986), but lung
epithelial cells (Marchlinski et al., 1982) as well as extra-lung cell types such as Kupffer
cells, skin macrophages, and peripheral neutrophils can be affected (Adams et al., 1985)
as well as the cornea and conjunctiva (D'Amico and Kenyon, 1981).  There is evidence
that phospholipidosis is caused by an inhibition of lysosomal phospholipase A, an
enzyme responsible for phospholipid degradation (Martin, 1990).
The more damaging aspects of AIPT are the pneumonitis, or inflammation, and
pulmonary fibrosis, both of which can be fatal (Mason, 1987).  The inflammatory
response involves a thickening of the alveolar walls and the variable infiltration of
inflammatory cells into the interstitial and alveolar spaces (Martin and Rosenow, 1988a)
possibly associated with edema (Kennedy et al., 1987).  AD-induced inflammation
involves the recruitment of specific inflammatory cells, such as polymorphonuclear
4leukocytes (PMNs or neutrophils), lymphocytes, plasma cells, eosinophilic leukocytes
(eosinophils), and in some cases increased monocytes or macrophages (Akoun et al.,
1986; Martin and Rosenow, 1988a; Martin and Rosenow, 1988b).  Inflammatory cells are
capable of releasing toxic species, such as reactive oxygen species (ROS) and damaging
proteases, as well as inflammatory mediators such as cytokines and chemokines that can
exacerbate the existing condition (Laskin and Pendino, 1995).  ROS damage includes
lipid peroxidation, protein polymerization, and DNA strand breakage (Nakazawa et al.,
1996).  Therefore, inflammation can lead to damage of the host lung cells and tissues.
Tumor necrosis factor (TNF)-α is widely believed to be the primary regulatory
cytokine of many inflammatory processes.  TNF-α production is regulated by a TATA
box and promoted through a number of regulatory sites including NF-κB, CRE, AP-1,
and AP-2 (Luster et al., 1999). TNF-α is also regulated via mRNA translation rates and
stability; lipopolysaccharide (LPS) stimulation leads to a 100-fold accumulation of TNF-
α message (Lindstein et al., 1989; Han et al., 1991).  Following i.v. administration of
LPS to humans and experimental animals, serum TNF-α levels peak within two hours
before falling to baseline undetectable levels at four hours (Hesse et al., 1988). TNF-α in
turn stimulates the production for other inflammatory mediators such as IL-1, IL-6, IL-8,
macrophage inflammatory protein (MIP)-2, granulocyte macrophage-colony stimulating
factor (GM-CSF), intracellular adhesion molecule (ICAM)-1, and endothelial leukocyte
adhesion molecule (ECAM)-1 (Luster et al., 1999).  These mediators can then act to
enhance vascular permeability and recruit and activate leukocytes involved in the
inflammatory response.  IL-6 is produced by T-cells and macrophages and acts to
stimulate B-cell proliferation and differentiation into antibody-forming cells (Kishimoto
5and Hirano, 1988).  Inflammation is usually resolved quickly, possibly involving the anti-
inflammatory cytokine IL-10 and soluble cytokine receptors that act to bind pro-
inflammatory cytokines away from cellular receptors (Suffredini et al., 1999).  Chronic
inflammation in the lungs may lead to the destruction or restructuring of parenchymal
tissue, leading to a thickening of the alveolar walls and collagen deposition known as
pulmonary fibrosis (Ward and Hunninghake, 1998).  AD-induced fibrosis may be diffuse
or focal, and also may be interstitial or intra-alveolar.
Pulmonary fibrosis is the accumulation of interstitial collagen fibers, which
results in a thickening of the alveolar septa and a decrease in the ability of the lungs to
expand to full capacity.  Therefore, the fibrotic lung has less compliance and a reduced
capacity to accomplish gas exchange than a normal lung (Poli and Parola, 1997).  While
the other pulmonary side effects of AD are potentially reversible, fibrosis is irreversible
once it develops (Akoun et al., 1986; Mason, 1987; Martin and Rosenow, 1988a; Martin
and Rosenow, 1988b).  The development of fibrosis may be linked to the repair of lung
damage, whether caused by a toxic insult or chronic inflammation.  Following lung cell
death or the recruitment of inflammatory cells, mediators are released that recruit and
activate fibroblasts and smooth muscle cells to the alveolar septa and alveolar spaces
(Poli and Parola, 1997; Ward and Hunninghake, 1998; Paine and Ward, 1999).  Several
signaling mechanisms have been implicated in the development of pulmonary fibrosis.
TNF-α is important in various ways, including induction of inflammatory cell adhesion;
initiation of the cytokine cascade; enhancement of a procoagulant environment;
immunomodulation of lymphocytes; mitogenesis of mesenchymal cells; regulation of
apoptosis; and regulation of collagen synthesis and reabsorption (Lasky and Brody,
62000). Also, TNF-α is key in the recruitment of various cell types to the lungs, including
platelets and eosinophils, which themselves can release potent profibrotic mediators.
These include Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor
Beta (TGF-β). PDGF is one of the most potent mesenchymal cell mitogens, and has been
seen in several models of pulmonary fibrosis with differing etiologies (Robledo and
Mossman, 1999; Lasky and Brody, 2000).  TGF-β is secreted by several pulmonary cells
types, including macrophages, eosinophils, epithelial cells, endothelial cells, and
fibroblasts, and acts to increase extracellular matrix synthesis while inhibiting matrix
degradation (Lasky and Brody, 2000; Levi-Schaffer et al., 1999).  Intracellular signaling
cascades involved in these cellular responses include mitogen-activated protein kinases
(MAPK) and NF-κB.  Activation of transcription factors such as NF-κB and AP-1 have
been linked to changes in early response genes such as c-jun and c-fos, which may govern
proliferation and apoptosis in various cells (Robledo and Mossman, 1999).  Thus, similar
factors may be involved in both pulmonary inflammation and fibrosis.  The role chronic
inflammation plays in the development of AD-induced pulmonary fibrosis in not yet
clear, but it may be a necessary factor in its development.
Current treatment for AIPT involves a reduction or elimination of the drug
dosage, leaving the patient susceptible to the original arrhythmia, and sometimes
corticosteriod therapy, which is accompanied by its own set of undesirable effects
(Martin and Rosenow, 1988b).  Furthermore, toxicity may recur when the steroid
treatment is halted (Joelson et al., 1984).
While several potential mechanisms for the development of AIPT have been
previously proposed and studied, the actual pathogenesis of AIPT is unknown (Massey et
7al., 1995; Reasor and Kacew, 1996).  Possible theories include the involvement of
oxidative mechanisms (Kennedy et al., 1988; Vereckei, 1993), dependence on
immunological mechanisms and the involvement of hypersensitivity (Akoun et al., 1984),
the development of phospholipidosis (Martin, 1990), direct cytotoxicity (Martin and
Howard, 1985), drug burden (Camus and Jeannin, 1984), and drug-induced alterations in
membrane properties (Honegger et al., 1993).
While these theories are more easily studied in animal models of AIPT, there are
some data from human patients that pertain to several.  Phospholipidosis is generally
present in all patients taking AD whether or not they present any other symptoms of the
toxicity (Kennedy et al., 1987); therefore it is unclear what role the phospholipidosis
plays, if any, in the development of the other aspects of the toxicity (Reasor and Kacew,
1996). While patients displaying other manifestations of AIPT also display
phospholipidosis, the mere presence of phospholipidosis does not necessarily mean that
other forms of the toxicity will develop.
There is evidence both for and against an immunological basis for human AIPT.
Evidence for a hypersensitivity reaction in a patient with AD-induced pneumonitis was
reported by Akoun et al. (1984) when bronchoalveolar lavage (BAL) revealed
lymphocytosis with an inverted helper/suppressor T cell ratio.  Another study found
similar results in five patients, who subsequently responded well to corticosteriod
therapy, also indicative of an allergic response (Venet et al., 1984).  A humoral response
to a lung-AD complex in a patient who had taken AD for approximately six months was
also reported (Fan et al., 1987).  Martin and Rosenow (1988b) examined the BAL fluid
from 14 patients with AIPT and found five with normal BAL cell profiles, four with
8lymphocytosis, three with a predominant neutrophilia, two with significant eosinophilia,
one of which was also presenting with lymphocytosis.  These differences in cell profiles
may reflect different times in the development of the toxicity or differing mechanisms
behind each case.  Studies do exist that contain no evidence for immunological
involvement (Adams et al., 1986; Liu et al., 1986; Kennedy et al., 1987).  It is therefore
possible that AIPT has various causes in different cases or is multi-factorial (Reasor and
Kacew, 1996).
Attempts to elucidate the etiology of AIPT may be more direct when using animal
models for the toxicity.  The functional effects of phospholipidosis on lung cells have
been studied in animal models (Wilson and Lippmann, 1993; Wilson et al., 1993; Reasor
et al., 1996) with inconsistent results being reported, although the condition does not
seem to be particularly deleterious alone.
Several labs have studied the possible role of oxidative mechanisms in the
development of AIPT utilizing animal models.  One animal study implicated oxidative
processes occurring in the lung by showing decreased levels of the endogenous
antioxidant glutathione, both reduced and oxidized, in the lungs of hamsters following a
single intratracheal (i.t.) AD treatment (Leeder et al., 1996).  Also, the ability of
antioxidants to prevent AD-induced damage to isolated and perfused rabbit lungs was
shown in another report (Kennedy et al., 1988).  In contrast, Leeder et al. (1994) found
that pretreatment of hamsters with antioxidants did not prevent the development of
pulmonary toxicity following i.t. AD treatment.  It is important to note, however, that
animals were pretreated with antioxidants for only three days prior to AD administration,
and no antioxidant treatment was given after AD treatment.  Furthermore, Wang et al.
9(1992) reported attenuation of AD-induced phospholipidosis and fibrosis in hamsters by
the administration of taurine and/or niacin. The mechanisms of this protection are not
clear, but taurine could be acting as an antioxidant.  Blake and Reasor (1995a) reported
that BAL cells recovered from hamsters following intratracheal AD administration
produced more phorbol myristate acetate (PMA) stimulated luminol-dependent
chemiluminescence (LDCL) than cells from control animals.  These increases were
diminished by superoxide dismutase and catalase addition, indicating the possible
involvement of superoxide anion and hydrogen peroxide or their subsequent products in
the response.  It is not known what role these oxidants play in the development of AIPT.
Aromatic iodine derivatives are known to deiodinate via a free radical mechanism
(Levy et al., 1973), and it has been shown that AD can generate free radicals under
certain conditions. Much of the interest in AD free radical production stems from studies
examining the mechanism of cutaneous photosensitivity, which occurs in 75-100% of
patients receiving AD (Harris et al., 1983).  Hasan et al. (1984) induced cytotoxicity to
erythrocytes and lymphocytes after photoactivation of AD with ultraviolet (UV)
irradiation.  This damage was found to be both partially oxygen dependent and
independent.  Desethylamiodarone (dAD), the primary metabolite of AD in vivo (Brien et
al., 1987), was more phototoxic than AD.  The photolysis of AD was first studied
spectroscopically by Li and Chignell (1987).  Deiodination following UV exposure was
shown in both AD and dAD, and aryl radical formation was demonstrated with spin
trapping and electron spin resonance (ESR) spectroscopy in aerobic and anaerobic
aqueous solutions.  Paillous and Verrier (1988) confirmed this UV-induced deiodination
and the structures of the products resulting from this photolysis.  The resulting aryl
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radical was shown to abstract a hydrogen atom from the solvent.  They also demonstrated
the production of singlet oxygen, formed by the reaction of AD and molecular oxygen,
and the presence of hydroxyl radical.  Therefore, oxygen-dependent (superoxide,
hydrogen peroxide, and singlet oxygen) and oxygen-independent (direct hydrogen
abstraction) mechanisms of free radical formation have been implicated following UV-
induced deiodination of AD.
While these results have direct implications for studies of the phototoxicity of
AD, the involvement of free radicals in AIPT remains unclear.  Vereckei et al. (1993)
speculated that aryl radical may be produced from AD during in vivo metabolism, but
was unable to prevent pulmonary toxicity or liver microsomal lipid peroxidation induced
by high-dose oral AD treatment to rats with dihydroquinoline-type antioxidants.  The
same group however did use vitamin E and silimarin separately to reduce AD-induced
elevations in conjugated dienes in liver homogenates from AD-treated rats (Agoston et
al., 2001), though the role of free radical generation in these changes was never actually
established.
AD has also been postulated to act as a free-radical scavenger.  Ide et al. (1999)
protected cultured cardiac myocytes with AD from hydroxyl radicals produced by the
Fenton reaction as well as used AD to quench hydroxyl radicals during ESR analysis.
Ribeiro et al. (1997) has shown AD inhibited lipid peroxidation in rat liver mitochondrial
membranes challenged by an iron-dependent oxygen radical generating system.  Thus it
seems that AD has both free radical producing and scavenging properties depending on
the conditions in which it is examined.
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Other studies using in vitro nonpulmonary cell culture systems have shown the
cytotoxic effects of AD could not be prevented by antioxidants or free radical scavengers
except for vitamin E, which was thought to exert membrane-stabilizing effects and not
acting as an antioxidant (Kachel et al., 1990; Ruch et al., 1991).  Honegger et al. (1995)
utilized vitamin E to inhibit the development of phospholipidosis in cell culture by
inhibiting the uptake of the drug into the cells.  Also, when hamsters were supplemented
with vitamin E in their diets (500 IU/kg chow) for 6 weeks prior to and 21 days following
i.t. AD administration, AD-induced elevation of lung hydroxyproline, a biochemical
indicator of fibrosis, and lung disease index were inhibited (Card et al., 1999).  However,
vitamin E supplementation also decreased hydroxyproline levels and disease index in
control animals that received the AD vehicle as well.  The effects of vitamin E
supplementation of patients with AIPT have not been reported.
A review of animal evidence of an immunological cause of AIPT found
inconsistent results as well (Reasor and Kacew, 1996).  Findings of increased release of
certain inflammatory cytokines by alveolar macrophages from animals given oral AD
have been reported (Reasor and Kacew, 1996).  Studies that find the elevation of
lymphocytes in the bronchoalveolar lavage fluid of orally AD-treated rats (Wilson et al.,
1989) and an influx of neutrophils and eosinophils into the lungs of hamsters treated with
AD intratracheally (Cantor et al., 1984; Blake and Reasor, 1995b) implicate immune
processes being active following AD administration.  Lymphocytes and eosinophils are
associated with hypersensitivity reactions, indicating a possible role of similar immune
reactions in AIPT in some animal models. Eosinophils, once recruited, have the ability to
release mediators such as platelet-activating factor, leukotrienes, prostaglandins,
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histamine, cytokines, chemokines, and cationic proteins which have the potential to
augment the inflammatory response and induce tissue damage and dysfunction (Hogan
and Foster, 1997).  The role of eosinophilic inflammation in the development of AIPT is
not yet fully elucidated.
Blake and Reasor (1997) reported that treatment of hamsters with the
corticosteriod dexamethasone prior to and following i.t. AD administration prevented the
development of pulmonary fibrosis but did not block neutrophil influx or albumin
leakage into the alveoli.  The interdependence of immune reactions and fibrogenesis is
not entirely clear, and the role of initial inflammation again warrants further study.
However, dexamethasone may have a direct effect on fibroblasts to decrease collagen
production (Ramalingam et al., 1997).
Amiodarone is usually administered to patients orally, although an intravenous
preparation exists that can be used for cardiac emergencies in hospital settings.  Attempts
to reproduce the pulmonary toxicity seen in humans with animal models have met with
limited success.  Oral AD treatment of animals with moderate doses produces the
characteristic phospholipidosis.  However, animals seem resistant to the development of
the other more damaging inflammatory and fibrogenic aspects of AIPT (Heath et al.,
1985; Riva et al., 1987) except in a few studies when animals were given very high AD
doses or treated for an inordinate amount of time (13 months) (Carvalho et al., 1996) and
inflammatory cells (Wilson et al., 1991; Carvalho et al., 1996) or fibrosis (Vereckei,
1993; Carvalho et al., 1996) were found.  Conversely, inflammation and fibrosis have
been induced by the i.t. administration of AD to hamsters (Cantor et al., 1984; Daniels et
al., 1989; Wang et al., 1992; Blake and Reasor, 1995a) and rats (Reinhart et al., 1996),
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but this method lacks the phospholipidosis induced by chronic oral AD administration.
However, since the role of phospholipidosis in the development of AIPT is in question,
and inflammation and fibrosis are the more damaging and life-threatening aspects of the
toxicity, the i.t. route of administration is currently favored in animals studies of AIPT
(Reinhart et al., 1996; Reinhart and Gairola, 1997; Card et al., 1999).
The first report of i.t. AD administration to animals was from Cantor et al. (1984)
in which hamsters were given a single i.t dose of AD and evaluated for pathological
reactions.  They found an initial inflammatory response to both AD and vehicle (normal
saline with 2% Tween 80 and 1% benzyl alcohol) followed by resolution and a secondary
inflammatory response in AD-treated animals involving eosinophilia and progressing to
fibrosis.  As this secondary response shared some common features with human AIPT,
they concluded that i.t. AD administration may be useful in examining the mechanisms
that underlie AIPT development.  They chose the i.t. route of administration because it
had been successfully employed to produce bleomycin-induced pulmonary fibrosis in
hamsters (Snider et al., 1978).  However, it has been subsequently noted that the
pathology of bleomycin-induced fibrosis in mice differs depending on the route of
administration employed, either i.t or i.v. (Lindenschmidt et al., 1986).  Intratracheal
bleomycin treatment leads to a rapid inflammatory response and relatively sooner fibrosis
development in central lesions than does i.v. bleomycin treatment, which causes a less-
pronounced inflammatory response and subpleural fibrotic lesions more similar to the
distributions seen in humans.  Thus the i.t. route of administration may change the
localization and the onset of pulmonary toxicity.  Intratracheal administration is more
commonly employed as a surrogate for inhalation for airborne toxicants, especially
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during screenings of multiple toxicants for multiple fractions of a complex toxicant, or
when inhalation techniques are not feasible due to technical considerations (Driscoll et
al., 2000).  However, the development of the i.t. AD model was based on the perceived
success of the i.t. model of bleomycin-induced pulmonary fibrosis, as i.t. AD produced
similar results.  The use of this route of administration has continued due to the
subsequent findings of the lack of inflammation and fibrosis development from oral AD
administration to animals.  Thus, the i.t. route of administration has been the most widely
employed animal model for the study of AD-induced inflammation and fibrosis in recent
years.
Models of AIPT have been developed in hamsters (Cantor et al., 1984; Daniels et
al., 1989; Wang et al., 1992; Rafeiro et al., 1994; Leeder et al., 1994; Blake and Reasor,
1995a) and rats (Reinhart et al., 1996; Reinhart and Gairola, 1997) in an attempt to
elucidate the mechanisms by which this disorder develops.  Intratracheal instillation of
AD leads to an inflammatory reaction in hamsters (Blake and Reasor, 1995a) and a
fibrotic reaction in hamsters (Cantor et al., 1984; Blake and Reasor, 1995b) and rats
(Reinhart et al., 1996).  Little information exists concerning the inflammatory reaction to
i.t. AD in rats.  While the hamster has been the animal of choice for many studies of
AIPT, the rat model offers a greater potential for studies of the mechanisms that underlie
AIPT due to the greater availability of certain molecular reagents and tools.  A rat model
for AIPT could allow research into the specific mediators, such and cytokines and cell-
signaling molecules, of both the inflammatory and fibrotic responses.  Furthermore,
specific inhibitors could be used to ascertain the specific role of any single mediator.
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Therefore the development of a rat model for AIPT is important in the attempt to
elucidate mechanisms that may underlie the development of the toxicity.
Diagnosis of AIPT in patients taking amiodarone is difficult due to the lack of
specific symptoms and often the presence of confounding factors (Martin and Rosenow,
1988a). AIPT is usually diagnosed based on the symptoms of dyspnea as well as
radiological findings of diffuse pulmonary infiltrates (Nicholson and Hayward, 1989;
Butler and Smathers, 1985; Delany et al., 1993). Patients with concurrent cardiac or
respiratory disorders are more likely to go undiagnosed, and AIPT can be fatal in such
cases (Pitcher, 1992). A specific marker for the pulmonary response to AD could aid in
the early diagnosis of AIPT, possibly before overt toxicity develops. While several serum
biomarkers have been proposed for the monitoring of lung diseases, at present none have
been identified to detect the onset and progression of AIPT. Serum levels of mucin-1
were elevated in 8 out of 10 AD patients with AIPT, but mucin-1 levels were also
increased in AD patients that exhibited non-pulmonary toxicities (Devine et al., 1998).
Also, elevated serum lactate dehydrogenase (LDH) was found in a patient with AD-
induced pneumonitis (Drent et al., 1998). However, LDH is not lung-specific and can be
released into the blood in non-pulmonary toxicities.
Recently the serum levels of surfactant protein-D (SP-D) were found to be
increased in patients with idiopathic pulmonary fibrosis, interstitial pneumonia with
collagen disease, and pulmonary alveolar proteinosis (Honda et al., 1995). Since SP-D is
produced in the lungs by alveolar type II cells and is found in the fluid lining the alveoli
(Crouch, 1998), it may serve as a more specific marker for lung injury.  No studies as of
yet have examined the potential for SP-D to serve as a biomarker for AIPT.
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Because of the current prescribing trends of using AD as more often as a first-line
therapy to treat various types of arrhythmias, there is potential for a large patient
population to become afflicted by AIPT.  Research is needed to aid in the elucidation of
the mechanisms behind the development of AIPT, so that inhibitors of the toxicity can be
developed, and to identify a biomarker to aid in the early diagnosis AIPT, so that a
potentially fatal condition can be averted.
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Objectives
This study consists of three major objectives.  The first was to select an animal
model for AIPT that contained as many of the aspects of human AIPT as possible (i.e.
phospholipidosis, inflammation, and fibrosis) or at least the most damaging aspects of
human AIPT (inflammation and fibrosis).  The second objective was to characterize the
chosen model with regards to the development of initial damage, inflammation and
subsequent fibrosis, including any cellular activation that may be occurring that could
contribute to the damage observed.  Also, the potential for serum SP-D to act as a
biomarker for the toxicity was examined.  The third objective was to identify the
processes that occur soon after the AD dose is given, particularly focusing on the direct
role of the drug versus the role of inflammatory cell recruitment to the lungs as factors in
AD-induced damage.
Objective 1 was to determine the appropriate animal model to study AIPT.  Two main
routes of exposure exist for experimentally inducing AIPT in laboratory animals, either a
daily oral dose of AD or an intratracheal bolus instillation of AD directly to the lungs.
Each method develops different aspects of human AIPT and the appropriate model is
chosen based on the endpoints being assessed.  Oral AD treatment leads to lung drug
accumulation and phospholipidosis while i.t. AD produces inflammation and fibrosis
without drug and phospholipid accumulation.  To assess the two dosing protocols in rats,
a series of experiments was designed to examine several aspects of the pulmonary
response.  Rats were given AD or the sterile water vehicle either orally (150 mg/kg) daily
for 7 or 14 days until lavage or a single dose intratracheally (6.25 mg/kg) on day 0 and
lavaged on day 5.
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Objective 2 was to characterize the chosen model with regards to early damage to the
alveolar-capillary barrier, the number, type, and activation state of the inflammatory cells
involved, and the development of pulmonary fibrosis.  This was done by administering
two i.t. doses of AD (6.25 mg/kg bw in a 3.125 mg/ml solution) or an equivalent volume
of its vehicle on days 0 and 2 and subsequently examining the cells recovered by BAL or
the level of collagen deposition in the lungs.  Levels of SP-D in the serum were also
measured.
Objective 3 was to examine the events immediately following the i.t. administration of
AD or vehicle with regards to either cellular activation and potential inflammatory
regulator release or direct action of the drug.  The former was done by recovering the
lung cells soon after the first or second instillation and placing them in culture 24 hours.
The culture media could then assayed for these mediators.  The role of direct AD
cytotoxicity to the lungs was examined by analyzing biochemical indicators of damage as
well as utilizing ex vivo microscopy of intact tissue and cellular viability determination.
The ability of the drug to produce free radicals and the role of antioxidants in the toxicity
were also examined.
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Methods
Laboratory Animals: All studies were performed on adult male Fischer 344 rats (200-
300g; Hilltop Laboratory Animals, Scottsdale PA).  The animals were housed in the
Robert C. Byrd Health Sciences Center’s animal quarters and were allowed at least one
week to acclimate after arrival from the supplier.  Free access to food and water was
allowed unless otherwise indicated.
Oral Treatment: Animals were given amiodarone (150 mg/kg) or the water vehicle 5
days per week with a syringe and ball-tipped feeding needle, which was introduced
though the mouth and into the esophagus where the drug was administered.  Rats were
weighed regularly, and food was withheld from the water-treated control animals to
maintain similar weights between the treatment groups.  Animals given AD had free
access to food, and all animals had free access to water.
Intratracheal Treatment: Animals were anesthetized with Brevital (sodium
methohexital, 3 mg/kg), placed on a slanted board, and suspended from their maxillary
incisors as well as held by an elastic strap across the abdomen.  The tongue was held with
gauze and a syringe with a ball-tipped 20-gauge feeding needle was inserted transorally
into the trachea.  Amiodarone (6.25 mg/kg in a 3.125 mg/mL solution; 4.5 mM; pH 3.7)
or an equivalent volume of various control solutions (sterile water, HCl [4.5 mM], HCl
[pH 3.7], citrate buffer [pH 3.7; Lillie, 1948], and antioxidant solution [45 mM Trolox
and 22.5 mM ascorbate]) were then administered to the lungs.  The rat was removed from
the board and observed until consciousness is regained.  If necessary, air from the in-
house supply system was gently blown into the mouth or nose of animals experiencing
difficulty breathing due to obstructed airways.  Amiodarone or control solutions were
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administered in several different protocols; some studies involved just one instillation,
while others involved two separate instillations into the same animal at different time
points.  The first instillation occurred on what is designated day 0 and the second on
either day 2, meaning the rats receive two instillations two full days apart, or day 7,
where the rats receive two separate instillations one week apart.  The single intratracheal
dose protocol was reported by Reinhart et al. (1996), while the addition of a second
instillation had not yet been reported in rats.
Combined Dosing Protocol: During one experiment the dosing protocols were
combined so that the same animals were given amiodarone or vehicle both orally and
intratracheally.  Treatments started either concurrently, with animals receiving their first
oral and i.t. doses on day 0, or staggered, with one group of animals being treated for one
week orally before receiving the first of two i.t. doses.  In both groups oral treatment
continued for the duration of the experiment.  Control animals were also weight-matched
in this study by withholding food.
Bronchoalveolar Lavage: To harvest pulmonary cells for morphologic and functional
analysis, BAL was performed by washing out the lungs with aliquots of calcium-free and
magnesium-free phosphate-buffered saline (PBS).  The first BAL volume was
administered as 2mL per 100g body weight, and this volume was placed into the lungs
for 30 seconds with light massaging, withdrawn, and again instilled into the lungs for 30
more seconds.  Once withdrawn, this aliquot (designated the first BAL fraction) was kept
separate from the rest of the lavage fluid that was recovered.  BAL was continued with
similar aliquots and pooled until 50 mL of BAL fluid, containing BAL cells, were
recovered.  The recovered fluid was then centrifuged, the supernatant decanted, and the
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cells resuspended.  The first BAL fraction was centrifuged separately and the supernatant
was either assayed for lactate dehydrogenase activity and albumin content or aliquotted
and frozen at -20oC for subsequent albumin analysis (when LDH analysis was not done)
and at -70 oC for cytokine content analysis.  The cells from the first BAL fraction were
then pooled with the rest of the cells recovered from that animal, and were washed two
times.   Total BAL cells were counted using a Coulter Counter equipped with a
Channelizer (model Zb, Coulter Electronics, Hialeah, FL).  Aliquots of cells were then
attached to microscope slides via a cytospin (Shandon Cytospin II, Shandon Inc,
Pittsburgh, PA), dried, and stained with an automated slide stainer using Wright-Geimsa
stain (Hema-Tec 2000, Bayer Corp., Elkhart, IN).  Finally, the different cell types were
identified and counted under a light microscope and the percentage of total cells as well
as the total number of each cell type recovered from the lavage were obtained.
Serum Preparation: At the time of lavage, blood was drawn from each animal directly
from the heart using a 21-gauge needle and syringe.  The blood was allowed to clot and
then was centrifuged.  The serum supernatant was drawn off and frozen at -20oC for
subsequent surfactant protein analysis.
Analysis of Drug Accumulation: The accumulation of amiodarone and subsequent
metabolites, such as desethylamiodarone, was measured in BAL cells.   According to the
method of Reasor et al. (1988), the AD and its metabolites were extracted from harvested
BAL cells with acetonitrile, and the drug levels were measured using high-performance
liquid chromatography (HPLC) and compared to a standard curve produced from known
drug concentrations.  L-8040 was used as an internal standard.
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Analysis of Phospholipidosis: To index phospholipidosis in BAL cells, the cells were
harvested by lavage as previously described and subjected to lipid extraction by
chloroform/methanol (2:1, v/v) as described by Folch et al. (1957).  Then total lipid
phosphorus was measured by the method of Ames and Dubin (1960).  Briefly, samples
were ashed with 10% MgNO3 in 70% ethanol to liberate inorganic phosphorus.  The
resulting phosphorus was measured colorimetrically.
Analysis of Albumin: The integrity of the alveolar-capillary barrier was evaluated by
measuring the amount of albumin, a protein from the blood, in the first BAL fraction that
was recovered from the lungs during lavage.  BAL fluid albumin was determined
according to a Sigma Diagnostics method utilizing the reaction of albumin with
bromcresol green.  The reaction product was then measured with a spectrophotometer at
628 nm and quantified against known concentrations of bovine serum albumin.
Analysis of LDH Activity: Lactate dehydrogenase activity in the first BAL fraction was
used as an indicator of cellular death and injury.  LDH leaks from dead or damaged cells
when membrane integrity is lost.  LDH activity was determined by the reduction of
pyruvate coupled to the oxidation of NADH at 340 nm over time according to the method
of Wroblewski and LaDue (1955).  Measurements were performed with a Cobas Fara II
analyzer (Roche Diagnostics Systems, Montclaire, NJ).
Performance of Luminol-Dependent Chemiluminescence (LDCL): To measure the
release of oxidants from BAL cells, LDCL was performed as described by Antonini et al.
(1994) on a Berthold LB9505C Luminometer.  Rats treated with AD or water vehicle
underwent BAL, and the BAL cells were counted as previously described.  Luminol, used
as a bystander to produce CL when oxidized, was dissolved in DMSO and then diluted in
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PBS (pH 7.4).  The final luminol concentration in the assay cuvette was 10-5 M.  Phorbol
myristate acetate was used to activate the oxidative burst at a final cuvette concentration
of 2X10-6 M.  An unstimulated baseline LDCL production was obtained by omitting
PMA.  To selectively inhibit oxidant species and determine the nature of the LDCL
produced, the nitric oxide synthase inhibitor Nω-nitro-L-arginine methyl ester (L-NAME;
1 mM final concentration) and superoxide dismutase (SOD; 0.2 mg/ml final
concentration), a superoxide-scavenging enzyme, were added alone and combined to
designated replicates. Samples containing inhibitors were pre-incubated five minutes
prior to PMA addition and subsequent LDCL measurement. The final reaction volume
for all samples was 500 µl and the reactions were measured at 37oC for 20 minutes.
Integral CL counts were determined by KINB software for the Berthold 9505C
Luminometer.
Analysis of Fibrosis: Pulmonary fibrosis was evaluated several ways in these
experiments; biochemically, histopathologically, and with laser-scanning confocal
microscopy (LSCM) at either 28 or 42 days after initial i.t. AD or vehicle treatment.
Biochemical Quantification of Hydroxyproline: Hydroxyproline is an amino acid that is
relatively rare in most proteins, but is prominent in the left-handed helix of collagen
fibers.  An increase in lung hydroxyproline levels indicates an increase in lung collagen,
which is characteristic and definitive of pulmonary fibrosis.  Hydroxyproline was
measured based on the assay developed by Witschi et al. (1985).  The right-lung lobes of
treated or control animals were hydrolyzed in strong acid at 100oC for 72 hours to release
hydroxyproline.  The hydroxyproline was then oxidized and converted to a colored
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product that could be measured with a spectrophotometer at 560 nm, comparing the
samples with standard solutions of trans-hydroxyproline.
Histopathological Evaluation of Fibrosis:  Fibrosis was characterized histopathologically
by inflating and fixing the left lung with 10% formalin solution, embedding the tissue in
paraffin, and sectioning the tissue for the preparation of microscope slides.  Sections of 5
µm were made and stained with either hematoxylin and eosin or trichrome, a stain
specific for collagen fibers.  A veterinary pathologist (Dr. Ann Hubbs, HELD/NIOSH,
Morgantown, WV) then evaluated any pulmonary damage and fibrosis in these sections,
and returned a detailed report of the findings.
Laser Scanning Confocal Microscopy (LSCM): Fibrosis was quantitated in the left lung
lobes of AD- and water-treated animals at day 28 based on the method of Antonini et al.
(1999).  The left lung was inflated and fixed with 10% formalin, sectioned into blocks,
dehydrated in a graded series of ethanol washes, stained with Lucifer Yellow (0.1
mg/mL) for 24 hr, and embedded in Spurr’s epoxy for LSCM analysis (Rogers et al.,
1992). Images were recorded using a Sarastro 2000 (Molecular Dynamics, Inc.,
Sunnyvale, CA) laser scanning confocal microscope (Optishot-2, Nikon, Inc., Melville,
PA) fitted with an argon-ion laser.  Emission spectra >510 nm were diverted to a separate
photodetector and used to image lung tissue and cells.  Using a 20X objective, the tissue
areas (excluding large airways and blood vessels) of 25 random scans per block (3-4
blocks per animal; 75-100 scans per animal) were randomly scanned by Jenny Roberts
(HELD/NIOSH, Morgantown, WV).  An image field of 1024 µm x 1024 µm (1.05 x 106
µm2) was defined over a region of parenchyma entirely filling the field.  Using
ImageSpace software (Molecular Dynamics), threshold pixel intensity levels were
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established that defined lucifer yellow-positive and lucifer yellow-negative sites, thus
identifying the presumed connective tissue matrix material.  Fluorescent signals below a
pixel intensity value of 38 were thresholded out, which eliminated the measurement of
cells and debris within the air spaces.  The area of tissue stained above the intensity
threshold was obtained for each image.  All random scans of the lung tissue for each
treatment group were recorded ~3-5 µm from the top of the tissue block at a
photomultipier tube (PMT) setting of 450, pinhole aperture setting of 50 µm, and the
same laser voltage setting of 20 mW.  This analysis resulted in a data set expressed as
connective tissue (lucifer yellow-positive) area in µm2 per image field.  For statistical
analysis of difference between groups, all measurements per each animal were averaged,
and the mean tissue area/field of each animal was obtained (N=3 per treatment).
Surfactant Protein-D Levels: Levels of SP-D were assayed in the sera of naïve and AD-
and vehicle-treated rats at various time points by Kathy Shannon in the laboratory of Dr.
Robert Mason (National Jewish Medical and Research Center, Denver, CO.). Serum SP-
D levels were assayed with a sandwich enzyme-linked immunosorbent assay (ELISA)
technique. Rat SP-D, which was purified from lavage fluid from rats 28 days after silica
instillation according to the method of Shimizu et al. (1992), was used as a standard for
the assay. Polyclonal anti-rat SP-D rabbit IgG (10 µg/ml in 0.1 M sodium bicarbonate)
was prepared by the method of Shimizu et al. (1992) and bound to wells in microtiter
plates (Immulon I plates; Dynatech Laboratories, Alexandria, VA) at room temperature
overnight. The wells were then incubated with a 5% (wt/vol) solution of non-fat dry milk
in PBS (blocking buffer) to block non-specific binding. After washing, 100 µl containing
purified rat SP-D (0-20 ng) for standards or appropriately diluted serum samples were
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added to each well. Plates were then incubated for 90 minutes at 37o C and then washed
with 20% blocking buffer, 1% Triton X-100 (vol/vol) in PBS (antibody buffer). After
washing, 200 µl of anti-SP-D antibody-conjugated horseradish peroxidase (30 µg/ml in
antibody buffer) were added to the wells and the plates incubated for 90 min at 37o C.
After further washing with 1% Triton X-100 in PBS, 200 µl of the color-developing
agent (0.1% o-phenylenediamine, 0.015% hydrogen peroxide in 0.1 M citrate buffer, pH
4.6) were added. The reaction was carried out for 5 min at room temperature in a
darkened room and was stopped by the addition of 100 µl of 1 M sulfuric acid. The
absorbance at OD 490 nm was recorded with a Microplate Autoreader EL-311s (BIO-
TEC Instruments Inc., Winooski, VT).
Cell Culture: To assess certain products of BAL cells over time, cells were harvested by
lavage, counted, and cultured in EMEM 24 hours. The culture media consisted of Eagle’s
minimum essential medium (MEM; BioWhittaker, Walkersville, MD) supplemented with
1 mM glutamine (GIBCO, Grand Island, NY), 10 mM HEPES, 100U/mL of penicillin-
streptomycin (GIBCO), 100 µg/mL of kanamycin (GIBCO), and 10% (vol/vol) fetal
bovine serum (BioWhittaker), with a final pH of 7.4.  The medium was made using
endotoxin-free water (BioWhittaker) and sterile-filtered at 0.2 µm.  Cells were cultured in
24-well plates at a density of 2 x 106 cells/mL/well in duplicate in a 37oC incubator with
5% CO2.  Cells were cultured in duplicate either with or without 10 µg/mL LPS.  LPS
was added as a stimulant of the inflammatory response as a positive control and to obtain
maximal response.
NOx Assay:  After culture, the NO oxidation products nitrate (NO3) and nitrite (NO2),
collectively referred to as NOx, were assayed in the media.  Samples were first incubated
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with Escherichia coli nitrate reductase to convert NO3 to NO2.  Then NO2 was measured
colorimetrically with the Greiss reaction (Green et al., 1982).  NOx levels were
determined by comparing to sodium nitrite standards.  Conversion of NO3 to NO2 was
checked in every assay by measuring the formation of NO2 from NO3 standards.
Cytokine Levels: Levels of the pro- and anti-inflammatory cytokines TNF-α, IL-1β, IL-
6, and IL-10 were assayed in the media after the 24-hour culture period.  Cytokine
protein concentrations were determined with an enzyme-linked immunosorbent assay
(ELISA) immunoassay kit from Biosource International (Camarillo, CA).  This technique
is a sandwich ELISA that utilizes an antibody specific for each rat cytokine (depending
on the kit) coating the wells of a microtiter plate.  Samples, including standards of known
cytokine concentrations, were added to the wells along with a biotinylated second
antibody in the solution phase. This mixture was allowed to incubate while the rat
cytokines bind simultaneously to the capture antibody on the plate as well as the
secondary biotinylated antibody at a second site.  After washing with an automated plate
washer to remove excess secondary antibody, a streptavidin-labeled peroxidase enzyme
was added.  This bound to the biotinylated antibody to complete a four-membered
sandwich.  After a second washing removed the excess (unbound) enzyme, a substrate for
the peroxidase enzyme was added.  The bound enzyme acted upon this substrate to
produce a colored product.  Once this reaction was stopped and the color stabilized, the
intensity of the color produced was directly proportional to the concentration of
cytokine present in the original sample.  This color was read with a plate
spectrophotometer and concentrations of unknowns were compared to known cytokine
standards using Softmax Pro software.
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In Situ Viability Determination Using LSCM: At 15 minutes, 1 hour, and 3 hours after
the first intratracheal AD administration, and on day 3 after installations on day 0 and 2,
rats were anesthetized and their lungs inflated with ethidium homodimer solution (4 µM;
Molecular Probes, Eugene, OR) to a pressure of 30 cm of water for 15 min.
Cryosections for Quantification: The lungs were then cryopreserved with Tissue-Tek
O.C.T. compound (Sakura Finetek, Inc., Torrence, CA) and frozen in liquid nitrogen.
Cryosections were made (10 µm thick), vapor-fixed with 2% paraformaldehyde, and
counter-stained with YO-PRO-1 (2µM; Molecular Probes, Eugene OR).  For each
treatment at each time point, 150-250 fields of fluorescently labeled lung tissue were
randomly scanned using a Sarastro 2000 (Molecular Dynamics, Inc., Sunnyvale, CA)
laser scanning confocal microscope (Optishot-2, Nikon, Inc., Melville, PA) fitted with an
argon-ion laser.  Micrographs were recorded by Jenny Roberts (HELD/NIOSH,
Morgantown, WV) through a 40X objective using a 488-nm laser line.  All random scans
of lung tissue for each group were recorded at the same PMT setting of 490, pinhole
aperture setting of 50 µm, and the same laser voltage setting of 20 mW.  Total cells
(green) and ethidium homodimer-positive cells (red) were counted using ImageSpace
software (Molecular Dynamics, Sunnyvale, CA).  Cells with both stains appear yellow
and are also counted as ethidium homodimer-positive.  For statistical analysis, all fields
from each treatment and time were pooled, and comparisons were made between each
time and treatment.
Fixation for Intact Tissue Analysis: The lungs were inflated with 2% paraformaldehyde
solution to a pressure of 30 cm of water for 6-8 hours. The lungs were then removed,
grossly sectioned, and counter-stained with YO-PRO-1 (2µM). Tissues were then imaged
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with LSCM using a 20X water-immersion objective at the same settings as above.
Three-dimensional images were generated from the reconstruction of serial optical
sections of tissue using Voxel View Ultra software (Vital Images, Inc., Fairfield, IA).
Free Radical Measurements: Electron spin resonance with and without spin trapping
was used to examine free radical generation with the assistance of Stephen Leonard
(HELD/NIOSH, Morgantown, WV).  While direct radical measurement was used to
detect longer-lived species, spin trapping was necessary to examine highly reactive
radicals.  Spin trapping involves the addition reaction of a short-lived radical with a
diamagnetic compound (i.e. spin trap) to form a relatively long-lived free radical product,
termed the spin adduct, which can be studied with conventional ESR.  The intensity of
the spin adduct signal corresponds to the amount of short-lived radical trapped, and the
pattern of hyperfine splittings of the spin adduct are generally characteristic of the
original, short-lived, trapped radical. To determine the presence of aryl and hydroxyl
radicals, 5, 5-dimethyl-1-pyrroline N-oxide (DMPO) was used as a spin trap in these
studies.  Measurements were made with a Bruker Instruments Inc. ESP 300E
spectrometer and a flat cell assembly (Billeria, MA).  Spex 300 software (Clarksville,
MD) was used for data collection and analysis.  The Fenton Reaction (FeSO4 + H2O2)
was used to generate hydroxyl radicals as a positive control.  Hydroxyl signals were
quantified and compared by measuring and averaging the height of the two center
(doublet) peaks (in mm).  Reactants were initially mixed in test tubes and transferred to
quartz flat cells for analysis. Final concentrations for reactants are listed in figure
legends.  Enzymes indicated as heat-inactivated were placed in a boiling water bath for at
30
least 10 min.  Oxygen consumption of AD solution (25 mg/mL) was performed on a
Gilson oxygraph over 20 minutes.
Statistics: All data are presented as means ± SEM.  Comparisons between two means
were analyzed using a student “t” test between mean values; all other data were analyzed
using the appropriate ANOVA (one-way for multiple comparisons at a single time-point;
two-way for multiple comparisons and time-points) followed by Tukey’s protected “t”
post-hoc test.  Statistical significance was established when p<0.05.
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Results
The first objective of the project was to identify an appropriate rat model for the
study of AIPT.  The presentations of oral AD versus i.t. AD were compared.  Rats were
given AD or the sterile water vehicle either orally (150 mg/kg) daily for 7 or 14 days
until lavage or a single dose intratracheally (6.25 mg/kg) on day 0 and lavaged on day 5.
Figure 2 shows the accumulation of AD or its primary metabolite desethylamiodarone in
BAL cells after 7 and 14 days of oral treatment as determined by HPLC analysis.  Drug
levels were not detected in any cells from control animals.  Drug levels were detected in
macrophages from i.t.-treated rats at day 5, but the levels were below the quantifiable
range of this technique.  Figure 3 shows the lipid phosphorous levels in BAL cells from
rats receiving either oral AD or the water vehicle for 7 days.  Oral AD treatment resulted
in a significant increase in lipid phosphorous, indicating an increase in cellular
phospholipid content.
In order to assess any differences in cellular activation following oral or i.t. AD
treatment, an experiment was conducted in which rats were treated either orally with AD
or water for 7 days or rats were given a single i.t. dose of AD or water on day 0.  Rats
were lavaged either on day 7 for the orally treated group or day 5 for the i.t.-treated
group.  The BAL cells were then cultured for 24 hours in the presence or absence of LPS.
After culture, levels of NO2 or NO 3, stable products of NO and oxygen reactions
collectively referred to as NOx, were assayed.  Figure 4A shows that NOx production
from BAL cells from rats treated orally with AD was not different than from cells from
rats treated with water.  Conversely, Figure 4B shows that non-LPS-stimulated BAL
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cells taken from rats treated intratracheally with AD produced significantly more NOx
than those treated with i.t. water.
Another and perhaps more direct method to assay oxidant production is to use
luminol-dependent chemiluminescence.  To determine the appropriate vehicle for
subsequent studies with i.t. AD, an experiment was performed to compare the effects of
the vehicle used to deliver the AD on BAL cell LDCL.  AD was given to rats i.t. on day 0
either suspended in sterile normal saline or dissolved in sterile water at the same
concentration (6.25 mg/mL).  Figure 5 shows that, while there are no statistically
significant differences, there is a trend for AD in water to increase LDCL when rats are
lavaged at day 5.  To maximize the potential response, AD dissolved in sterile water
would be used for subsequent instillations.
To further compare cellular activation between the two dosing routes, LDCL was
compared between BAL cells taken from rats either treated orally with AD or vehicle for
7 days or treated once with i.t. AD or vehicle on day 0 and lavaged on day 5.  Figure 6
shows that there is a trend for BAL cells from rats treated with i.t. AD to produce more
LDCL than cells treated with i.t. water or oral AD or vehicle, although statistical
significance was not attained.  Also, more inflammatory cells were recovered by BAL
from i.t. AD-treated rats than the i.t. water vehicle or than the oral AD or vehicle
treatments (results not shown).  The i.t. route of administration with AD dissolved in
sterile water tended to be the most inflammatory and activating route of administration
for the short-term endpoints of inflammation, LDCL activation, and NOx production.
This protocol of a single i.t. dose of  AD did not lead to significantly elevated
hydroxyproline levels at day 28  as had been reported in the rat with this technique
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(Reinhart et al., 1996).  In attempt to produce a more consistent and significant fibrosis, a
second i.t. dose of AD or vehicle was added to the dosing regimen.  To determine when
to administer the second dose, an experiment was performed that compared either giving
the doses of AD or vehicle on days 0 and 2 or giving the doses on days 0 and 7, the latter
a protocol used in the hamster to induce fibrosis (Blake and Reasor, 1995b).  Figure 7
shows that the day 0 and 2 protocol produces a significantly elevated right-lung
hydroxyproline response in the AD-treated animals at day 28 where the day 0 and 7
protocol does not.  Dosing on days 0 and 2 was determined to be the more effective
protocol and was used for subsequent experiments involving fibrosis and the events prior
to fibrosis development.  To determine the appropriate time to analyze fibrosis, right-lung
hydroxyproline levels were assayed at both day 28 (4 weeks) and day 42 (six weeks)
following i.t. AD or vehicle treatment at days 0 and 2.  No differences were found
between the two time-points (results not shown), implying that by 4 weeks maximal
fibrosis is reached.
In an attempt to elevate right-lung hydroxyproline levels even further and develop
a more physiologically relevant model containing phospholipidosis, inflammation and
fibrosis, a study was performed that combined both the day 0 and 2 i.t. dose with a daily
oral dose (150 mg/kg) of  AD or vehicle.  Two combined dosing protocols were used;
rats were either started concurrently with the day 0 i.t. of  AD or water and the first oral
AD or water dose, or they were pretreated orally with AD to establish the characteristic
lung drug accumulation and phospholipidosis for 7 days before being given the first of
two i.t. AD or vehicle doses.  For comparison, two other treatment groups were included
in the experiment; first, a group that only received daily oral AD for 28 days, and second,
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a group that only received i.t. AD on days 0 and 2 with no oral treatment.  The control
group was given both daily water orally and a water i.t. on days 0 and 2.  Food was
withheld from the controls to match the weight loss experienced by the three orally AD-
treated groups.  Other controls were excluded as this was a preliminary experiment to
determine the future dosing regimen.  Figure 8 shows the results of this experiment.
Oral AD treatment failed to elevate right-lung hydroxyproline levels, and in fact may
have been protective against fibrosis in the orally pretreated group.  Since additional drug
treatment did not elevate fibrosis above the levels found in the i.t.-only group, the i.t.-
only protocol was chosen for the subsequent characterization studies.
 The second objective of the study was to characterize the chosen model of AIPT,
with i.t. AD doses (6.25 mg/kg) at days 0 and 2.  The potential use of serum SP-D as a
biomarker for AIPT in the model was also examined.  The fibrotic reaction was
characterized biochemically, histopathologically, and by using LSCM with Lucifer
Yellow staining. Increases were found in right-lung hydroxyproline levels at day 28 in
AD-treated rats (Figure 9), and at day 28, minimal to mild, multifocal, interstitial
pulmonary fibrosis was found in all rats treated with AD on days 0 and 2 (Figure 10). An
increase in lung tissue area similar in magnitude to the hydroxyproline increase was
found with LSCM, indicating septal thickening (Figures 11 and 12).  To examine the
early events involved in the toxicity, rats were treated on day 0 and 2 with intratracheal
AD (6.25 mg/kg in a 3.125 mg/mL solution) and were subjected to BAL at various time
points following dosing.  To analyze the integrity of the alveolar-capillary barrier,
albumin, a protein from the blood, was assayed in the first BAL fraction from AD- or
vehicle-treated rats (Figure 13).  Albumin was elevated at day 3 following AD treatment
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on days 0 and 2, showing initial damage and leakage from the blood to the airways after
AD administration.  Figure 14 shows total cell number recovered in the lavage fluid of
AD- or vehicle-treated rats.  Total cells recovered were elevated on both days 3 and 5
follow AD i.t. on days 0 and 2.  Figure 15 shows that most of the cells recovered are
alveolar macrophages, which are also significantly increased on days 3 and 5 following
AD treatment.  Figure 16 shows an increase in the number of PMNs recovered by lavage
on day 3.  Figure 17 shows an increase in eosinophilic leukocytes at days 3 and 5.
To assess the level of oxidant production and thus infer their level of activation,
PMA-stimulated LDCL was performed on the cells recovered by BAL.  Figure 18
indicates that the cells at day 3 are capable of producing more oxidants when stimulated.
Since the cells are activated on a per/cell basis, and significantly more cells are present
following AD treatment, potential oxidant production was calculated by multiplying the
LDCL by the total number of BAL cells recovered.  This is illustrated in Figure 19,
which shows the much greater potential for oxidant production due to the increased
number of activated cells at days 3 and 5 in the lungs of AD-treated rats.
To determine the oxidant species possibly involved in the LDCL response at day
3, specific inhibitors to various oxidants where utilized.  L-NAME is an inhibitor of nitric
oxide synthase, leading to reduced NO levels, while SOD in an enzymatic scavenger of
superoxide.  Figure 20 shows that SOD treatment inhibits a large portion of the light
production, indicating involvement of superoxide radicals, and while L-NAME also
inhibits significantly alone, combined with SOD it inhibits light production down to the
levels of non-PMA stimulated cells.  To determine if the incomplete inhibition of L-
NAME was due to its inability to penetrate the cells, L-NAME was pre-incubated for 10
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minutes with cells prior to LDCL rather than the standard 5, but inhibition was not
significantly increased (results not shown).  In another attempt to show increased levels
of NO production following AD treatment, rats treated with AD or vehicle on days 0 and
2 were lavaged on day 3, and the BAL cells were subsequently cultured 24 hours.  NOx
levels in the spent media were than assayed and displayed in Figure 21.  NOx levels
were elevated from non-LPS-stimulated cells from AD treated rats.
To assess the value of serum SP-D, a protein from the fluid lining of the lungs, as
a biomarker for AIPT in this model, the levels of SP-D were assayed in the serum of
naïve, vehicle-, and AD-treated rats. SP-D levels were elevated in rat serum following
AD treatment from day 3 through day 7, during the time of the initial damage and
inflammatory reaction (Figure 22).
To determine if any of the inflammatory response seen after AD treatment could
be attributable to the low pH of the AD solution (pH 3.7), rats were treated intratracheally
with either sterile water, AD in sterile water, or sterile water adjusted with HCl to match
the pH of the AD solution.  Rats were treated on days 0 and 2, and lavaged on day 3,
where cell counts and differentials were performed.  Figure 23 shows acidic water did
not alter alveolar albumin levels above normal water controls while AD solution does.
Figure 24 shows the acidic water did not induce the increase in total BAL cells recovered
during lavage as seen following AD treatment. Figure 25 displays the macrophage
number recovered, where only rats treated with AD showed a significant increase over
the sterile water control.  Figure 26 is the number of PMNs recovered, again with the
only increase coming after AD treatment.  Figure 27 shows that eosinophils were
recruited only after AD treatment and not after acidic water treatment.
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Objective 3 was to characterize the events occurring soon after i.t. AD or control
instillations to determine the direct role of the drug vs. the role of inflammation in the
toxicity.  To assess the ability of the initial i.t. to activate the BAL cells, rats were
lavaged 15 minutes, 1 hour, and 3 hours after i.t. treatment and cultured with and without
LPS.  NOx levels were then assayed in the culture media following a 24-hour culture.
Figure 28A shows that cells are not activated above control levels when not cultured
with LPS. Figure 28B shows the same time points with cells stimulated with LPS, and
again AD treatment does not significantly alter NOx production.
To examine the possibility that the inflammatory cytokine TNF-α was involved
during the early time points, rats were treated with a single i.t. dose of AD (6.25 mg/kg)
or sterile water and lavaged 1 or 3 hours later, or treated at days 0 and 2 and lavaged on
day 3.  BAL cells were then cultured 24 hours with and without LPS addition.  The
conditioned media was then assayed for TNF-α.  Figure 29A displays the TNF-
α produced by non-LPS-stimulated cells in culture.  No differences were seen between
TNF-α production from BAL cells from control and AD-treated animals.  However,
when these cells were stimulated with LPS, TNF-α production from cells from AD-
treated rats was inhibited at the 3-hour and 3-day time points (Figure 29B).  Finally,
TNF-α levels were assayed directly in the first BAL fraction, which represents the most
accurate sampling of the actual in vivo situation in the lung.  Figure 30 also shows a
significant inhibition of TNF-α at the 3-hour time point, with a trend of less TNF-α at all
time points in the lavage fluid of AD-treated animals.
In an attempt to identify other inflammatory cytokines that may be involved it the
inflammatory response, IL-1β was also assayed in the media from cultured BAL cells
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lavaged from rats 3 hours after i.t. administration of AD or vehicle.  Figure 31 indicates
that IL-1β production is also significantly inhibited in LPS-stimulated cells from animals
treated with AD vs. control.  While not significant, basal (non-LPS-stimulated) levels of
IL-1β tended to be decreased as well.  Other cytokines examined were the
immunomodulatory cytokine IL-6 and the anti-inflammatory cytokine IL-10.  Animals
were treated with i.t. AD or vehicle and lavaged 15 minutes later, the BAL cells were
cultured 24 hours with and without LPS, and IL-6 was measured in the conditioned
media.  No significant differences in IL-6 production were found (Figure 32A).  When
rats treated with i.t. AD or vehicle were lavaged at day 3 following instillations on days 0
and 2 and their BAL cells cultured, IL-6 production again was not significantly altered
from control (Figure 32B).  To examine the possible involvement of IL-10, levels were
also examined in the conditioned media from BAL cells.  However, no significant
differences were found in IL-10 production from cultured BAL cells, both basal and LPS-
stimulated, when BAL was 15 minutes after the instillation (Figure 33A) or on day 3
following instillations on days 0 and 2 (Figure 33B).
To examine the direct role of the drug vs. the effect of inflammatory cells in any
early damage that may be occurring after the i.t. administrations, albumin was measured
in the first BAL fraction obtained by lavage at 15 min, 1 hour, and 3 hours following the
initial i.t. AD or vehicle treatment or at day 3 following i.t. doses on days 0 and 2.
Figure 34 shows a massive damage to the alveolar-capillary barrier soon after AD was
administered.  LDH activity in the first BAL fraction was also significantly increased at
15 min post-AD i.t, but was not different from control at day 3 (Figure 35). An
experiment was designed to determine the effects of the acid instilled with AD in this
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early damage, since AD is a hydrochloride and also may act to buffer the pH of its
solution.  Citrate buffer (pH 3.7), HCl (equimolar to the AD solution; pH 2.5), AD (3.125
mg/mL; pH 3.7), or an equivalent volume of sterile water was intratracheally instilled to
rats and albumin (Figure 36A) and LDH activity (Figure 36B) in the first BAL fraction
was examined at 15 min.  Neither acid control significantly increased either damage
indicator above the levels found after i.t. sterile water treatment.
Exact cellular differentials of the BAL cells from AD-treated rats were not
possible at these early time-points due to the presence of unidentifiable amorphous cells,
possibly epithelial cells.  Cellular yield was very low from AD-treated animals, and
cellular viability of the BAL cells at 15 min was 29.8% (meaning a 70.2% mortality rate)
as determined by trypan blue exclusion.  Experiments utilizing various concentrations of
trypsin in the BAL fluid in an attempt to release macrophages that may have became
activated and attached to the lung parenchyma were unsuccessful in increasing cell yield
(data not shown).
LSCM was then used to examine the in situ viability of airway and parenchymal
cells after i.t. AD or water treatment.  Microscopic examination of grossly sectioned
tissue was performed at 15 min (Figure 37A) and 3 hours (Figure 37B) following the
initial i.t. treatment, and on day 3 (Figure 37C) following i.t. instillations of AD or water
on days 0 and 2.  Foci of massive cellular death or damage were found in the lung tissue
of animals receiving i.t. AD at 15 min and 3 hours.  To quantitate the effect of AD on
lung cell viability, thin sections were made from animals at 15 min after the initial i.t. of
AD or water (Figure 38).  The number of ethidium-positive and total cells in random
fields of lung tissue was determined, and the tissue was further categorized as either
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airway or parenchyma.  Figure 39A shows a significant increase in the number of
ethidium-positive cells in all areas 15 min after i.t. AD.  Figure 39B shows that the
average number of cells in each field was not different, indicating an adequate “N” value
for comparison.  Figure 40 shows representative fields on day 3 from animals that
received either i.t. AD or water on days 0 and 2.  The only difference in ethidium staining
that was found was in the parenchyma, with more ethidium-positive cells found in
animals that received AD (Figure 41A).   However, ethidium staining in general was
minimal compared to the levels found 15 min post-i.t. AD administration. Again there
were no differences in the average number of cells per field at day 3 (Figure 41B).
To examine the possibility of free radical production in AD solution, a series of
ESR experiments was performed.  Figure 42 shows a carbon-based radical in the AD
solution, presumably the AD molecule itself.  The radical signal can be reduced by
increasing the concentration of the drug in the solution, possibly by autoquenching.  No
O2 consumption was detectable over 20 min in a solution of AD (25 mg/mL).  Figure 43
shows that at least some of the carbon-based radical is present in the AD powder before it
is placed into solution.  By using DMPO as a spin trap, the production of hydroxyl
radicals can be examined.  Figure 44 is a time-course of hydroxyl radical production
from AD in water with various affectors.  The inhibitions by catalase and deferoxamine
indicate possible oxygen dependence (inhibitable portion) and independence (non-
inhibitable portion).  Formate competes with any hydroxyl in solution for the DMPO, but
in this case it raised the pH of the AD solution, increasing its apparent signal by
increasing the efficiency of DMPO to trap hydroxyl at the higher pH.  While formate was
the only chemical to change the pH of the AD solution measurably, another experiment
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was performed in PBS to maintain the pH of the solutions (Figure 45A), even though the
solutions became partly cloudy as some of the AD precipitated.  The inhibitor profile
remained the same, with reductions of hydroxyl signal following catalase and
deferoxamine indicating both possible oxygen dependence and independence.  Also the
effect of H2O2 was examined in this study by its exogenous addition.  The increase in
hydroxyl signal after H2O2 addition indicated the presence of something in the AD
solution that acted as a transition element.  Since chelation of metals by deferoxamine did
not completely inhibit hydroxyl production, several mechanisms of hydroxyl production
may have been occurring.  Attempts to add exogenous iron to infer the presence of H2O2
in the AD solution were unsuccessful as the charged iron forced AD out of solution.  This
was the case even after chelation of the iron with EDTA.  The last spectrum from each
sample for the time course of hydroxyl production in PBS is presented in Figure 45B.
Note the partial splitting of the hydroxyl-DMPO signal by formate, indicating trapped
hydroxyl radicals were free in solution.
In an attempt to determine if the effects of SOD and Cat were specific for their
actions or simply effects of exogenous protein, SOD and Cat were heat-inactivated.
Figure 46 shows that normal SOD and Cat did not follow their previous inhibitory
patterns in this experiment, but instead had no effect (SOD) or possibly enhanced (Cat)
hydroxyl production from AD.  However, heat-inactivated SOD showed the typical
inhibition pattern, indicating its effects in the earlier studies maybe simply due to the
protein in solution.  However, the heat inactivation of Cat completely changed its
inhibitory profile, possibly by denaturing the protein and releasing the active-site moiety
into solution, making it more available to interact with constituents of the solution.
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Thiol-containing antioxidants are known to adduct and quench aryl radicals, so N-
acetyl cysteine (NAC) and reduced glutathione (GSH) were separately added to AD
solution in PBS and hydroxyl production was examined by ESR (Figure 47).  However,
hydroxyl production was increased when either thiol antioxidant was present.  Neither
compound had an effect on the pH of the AD solution.  To examine the nature of the
parent-compound radical, DMPO spin-trapping was performed in chloroform.  Figure 48
shows a radical signal trapped by DMPO, and is presumably the AD parent compound.
When NAC was added, the presence of an N-acetyl cystyl radical was detected.  Thus
AD oxidized the antioxidant instead of adducting with it, and more hydroxyl radicals
were produced in solution when NAC is present.  Thus the N-acetyl cystyl radical may
interact with components of the solution to produce hydroxyl radical.  A preliminary
experiment attempting to use NAC to block i.t. AD-induced damage resulted in massive
lung hemorrhaging and death of the animal.
As Figure 42 indicated that the carbon-based radical signal decreased with
increasing AD concentration, Figure 49 shows a similar effect of AD concentration on
hydroxyl radical production at the highest concentration tested.  Higher concentrations of
AD could not be examined because the AD solution “solidified” as if it cross-linked.
These findings support the hypothesis that AD can be both a free-radical generator and
scavenger, depending on the conditions and concentration.
Attempts to examine free radical production in vivo were unsuccessful.  DMPO
was instilled with AD into rats, and then withdrawn, but even the expected baseline
hydroxyl-DMPO signal was absent.  Protocols involving the treatment of excised lungs,
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lung homogenates, and varying concentrations of BAL cells failed to yield any radical
signals (data not shown).
Figure 50 shows that UV light can induce aryl radical formation in AD solution
(3.125 mg/mL; 4.5 mM) in water (B), possibly by the deiodination of AD, but aryl
radical formation seems minimal under normal conditions (A).  The aryl peaks (B) split
with the hydroxyl peaks, producing a radical signal with more, but less substantial, peaks.
Also, the hydroxyl radical signal (without UV exposure) can be completely eliminated by
the simultaneous addition of Trolox (45 mM) and ascorbate (22.5 mM).  Because the
radical signal was eliminated, this solution was given i.t. to animals in an attempt to
modulate the toxicity and gain insight into the role of free radicals in the damage seen
after i.t. AD administration.  Figure 51A shows that having the antioxidant solution
together with AD increased the amount of albumin in the first BAL fraction at 15 min
post-i.t.  This indicates an even more severe damage to the alveolar-capillary barrier
occurs when the antioxidants are instilled in the same solution as AD.  The antioxidants
alone had no effect on the level of albumin in the first BAL fraction as compared to
sterile water.  Figure 51B shows no difference in LDH activity at 15 min in the first BAL
fraction between animals receiving i.t. AD with and without antioxidants in the solution.
Again the antioxidants alone had no effect on the LDH activity in the first BAL fraction
as compared to sterile water control.
To examine any structural changes that might have occurred when AD was heated
and dissolved in water vs. being readily dissolved in methanol, the two solutions were
compared using electrospray mass-spectroscopy.  Figure 52A shows the positive-ion
spectra of AD in both methanol (A) and water (B).  While several variations of the parent
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compound were found in each solution, differing only by a hydrogen, no evidence of a
mono- or di-deiodinated AD compound was found in the methanol solution.  There were
more peaks, however, in the AD-water solution, and one could possibly represent a di-
deiodinated AD (~393 Da).  However no evidence for mono-deiodinated AD was found,
which would have been expected if AD was undergoing deiodination.  Figure 52B shows
the negative-ion spectra of AD in both methanol (A) and water (B), and no evidence of
free iodine was found in either solution.  Free iodine would have been expected in
solution if AD were undergoing deiodination.  The ~393 Da peak could represent another
breakdown or recombination product of AD. 1H Nuclear Magnetic Resonance (NMR)
analysis of the AD powder confirmed that it is in its expected structure as drawn in
Figure 1 (data not shown).  Therefore, significant deiodination of AD in water under
normal laboratory conditions does not seem likely.
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Figure 2: Amiodarone and desethylamiodarone accumulation in BAL cells following
oral amiodarone treatment. Rats were treated daily (5 days/ week with AD [150
mg/kg]) until days 7 or 14 and were then subjected to BAL. Cellular drug levels were
measured by HPLC analysis. Values are means ± SEM.  N=2-6. *Significantly different
from day 7 value (p<0.05).
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Figure 3: Lipid phosphorous levels in BAL cells following one week of oral
amiodarone or vehicle treatment. Rats were treated orally with AD (150 mg/kg) for
one week (5 days/week) and then subjected to BAL. Lipid phosphorous levels were then
measured in the BAL cells. Values are means ± SEM. N=6. *Significantly different from
water control (p<0.05).
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Figure 4A: NOx production from BAL cells from rats given oral amiodarone or
vehicle one week. Rats were given AD (150 mg/kg) or vehicle one week (5 days/week)
and subjected to BAL.  BAL cells were then cultured 24 hours with and without LPS and
NOx was measured in the spent media. Values are means ± SEM. N=5-6. No significant
differences were found from water control (p<0.05).
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Figure 4B: NOx production from BAL cells recovered on day 5 from rats given
intratracheal amiodarone or vehicle on day 0. Rats were given i.t. AD (6.25 mg/kg) or
water on day 0 and subjected to BAL on day 5. BAL cells were then cultured 24 hours
with and without LPS and NOx was measured in the spent media. Values are means
± SEM. N=7-8. *Significantly different from non-LPS-stimulated water control (p<0.05).
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Figure 5: Integral LDCL counts on Day 5 following intratracheal amiodarone
administration in either sterile water or sterile saline or appropriate vehicle. Rats
were given i.t. AD (6.25 mg/kg) in saline or water on day 0 and subjected to BAL on day
5. BAL cells were then subjected to LDCL. Values are means ± SEM. N=3. No
significant differences were found (p<0.05).
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Figure 6: Integral LDCL counts from BAL cells recovered from rats treated either
with amiodarone or water orally for one week or treated intratracheally with
amiodarone or water on day 0 and lavaged on day 5. Rats were treated either orally
with AD (150 mg/kg) or water for one week (5 days/week) or intratracheally with AD
(6.25 mg/kg) or water on day 0 and subjected to BAL on day 5. BAL cells were then
subjected to LDCL. Values are means ± SEM. N=2-6. No significant differences were
found (p<0.05).
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Figure 7: The effects of two intratracheal dosing protocols on right-lung
hydroxyproline content. Rats were given i.t. AD (6.25 mg/kg) or water on either days 0
and 2 or days 0 and 7. At day 28 the right lung was removed and subjected to
hydroxyproline measurement. Values are means ± SEM. N=4. *Significantly different
from corresponding water control (p<0.05). #Significantly different from day 0 and 7
water control (p<0.05).
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Figure 8: Right-lung hydroxyproline levels following either daily oral amiodarone
treatment, i.t. amiodarone treatment, or combination treatments of both oral and
i.t. amiodarone or vehicle treatments.  Rats were either given daily oral AD (150
mg/kg 5 days/wk), i.t. AD (6.25 mg/kg) on days 0 and 2, daily oral AD and i.t. AD on
days 0 and 2 or vehicle started concurrently, or oral AD for 7 days followed by two i.t.
AD doses. Right lungs were removed 28 days after the initial i.t. treatment (or after the
initial oral treatment in the oral-only treatment group) and subjected to hydroxyproline
measurement. Values are means ± SEM. N=4-6. *Significantly different from double
water weight-matched control (p<0.05).
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Figure 9: Right-lung hydroxyproline content at day 28. Rats were instilled
intratracheally with sterile water or AD (6.25 mg/kg) on days 0 and 2. Right-lung lobes
were removed at day 28 and subjected to hydroxyproline analysis. Values are means
± SEM. N=8-9. *Significantly different from control (p<0.05).
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Figure 10: Effect of AD on left lung histopathology. Rats were instilled intratracheally
with sterile water or AD (6.25 mg/kg) on days 0 and 2. Left lungs were obtained at day
28, inflated, and fixed, and slides were prepared.  All tissues from control animals
exhibited normal lung architecture (N=5, data not shown). Lungs from all AD-treated rats
displayed minimal to mild, multifocal, interstitial pulmonary fibrosis (N=5). Fibrosis was
most frequently observed near alveolar duct regions. A representative field is shown from
an AD-treated animal. Arrows indicate areas of septal thickening and collagen deposition
evidenced by trichrome staining. Bar indicates 100 µm.
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Figure 11: Representative fields of lung tissue obtained by laser-scanning confocal
microscopy. Rats were instilled intratracheally with amiodarone (6.25 mg/kg) or an
equivalent volume of sterile water on days 0 and 2. Left lungs were inflated and fixed at
day 28, sectioned into blocks, stained with Lucifer Yellow, and analyzed by LSCM. This
technique measures the entire stained area of the alveolar septa, with alveolar cells and
debris removed from analysis by incorporating a threshold value. Colors indicate staining
intensity, from blue, green, yellow, red, to white, respectively, as the intensity increases.
Scale bars indicate 10 µm.
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Figure 12: Effect of AD on average lung tissue area stained by lucifer yellow. Rats
were instilled intratracheally with amiodarone (6.25 mg/kg) or an equivalent volume of
sterile water on days 0 and 2. Left lungs were inflated and fixed at day 28, sectioned into
blocks, stained with Lucifer Yellow, and analyzed by LSCM. Values are means ± SEM.
N=3. *Significantly different from control (p<0.05).
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Figure 13: Albumin in the first BAL fraction. Albumin in the first BAL fraction was
assayed at various time points following intratracheal instillations of sterile water or
amiodarone solution (6.25 mg/kg) on days 0 and 2. Naïve values are represented at day 0
and arrows indicate intratracheal treatments. Values are mean ± SEM. N=5-9.
*Significantly different from control (p<0.05).
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Figure 14: Total cells recovered by BAL. Rats were given intratracheal instillations of
sterile water or amiodarone (6.25 mg/kg) on days 0 and 2 and lavaged at various time
points following treatment. Total cell number recovered in the BAL fluid was
determined. Naïve values are represented at day 0 and arrows indicate intratracheal
treatments. Values are means ± SEM. N=5-9. *Significantly different from control
(p<0.05).
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Figure 15: Alveolar macrophages recovered by BAL. Rats were given intratracheal
instillations of sterile water or amiodarone (6.25 mg/kg) on days 0 and 2 and lavaged at
various time points following treatment.  The number of alveolar macrophages recovered
in the BAL fluid was determined. Naïve values are represented at day 0 and arrows
indicate intratracheal treatments.  Values are means ± SEM.  N=5-9.  *Significantly
different from control (p<0.05).
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Figure 16: Polymorphonuclear leukocytes recovered by BAL. Rats were given
intratracheal instillations of sterile water or amiodarone (6.25 mg/kg) on days 0 and 2 and
lavaged at various time points following treatment. The number of PMNs recovered in
the BAL fluid was determined. Naïve values are represented at day 0 and arrows indicate
intratracheal treatments. Values are means ± SEM. N=5-9.  *Significantly different from
control (p<0.05).
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Figure 17: Eosinophilic leukocytes recovered by BAL. Rats were given intratracheal
instillations of sterile water or amiodarone (6.25 mg/kg) on days 0 and 2, lavaged at
various time points following treatment, and the number of eosinophils recovered in the
BAL fluid was determined. Naïve values are represented at day 0 and arrows indicate
intratracheal treatments. Values are means ± SEM. N=5-9. *Significantly different from
control (p<0.05).
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Figure 18: Total PMA-stimulated luminol-dependent chemiluminescence counts
over 20 minutes from BAL cells. Rats were given intratracheal instillations of sterile
water or amiodarone (6.25 mg/kg) on days 0 and 2 and lavaged at various time points
following treatment. The recovered cells were subjected to LDCL with PMA stimulation.
Naïve values are represented at day 0 and arrows indicate intratracheal treatments. Values
are means ± SEM. N=5-9. *Significantly different from control (p<0.05).
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Figure 19: Potential oxidant production of total BAL cells. Rats were given
intratracheal instillations of sterile water or amiodarone (6.25 mg/kg) on days 0 and 2 and
lavaged at various time points following treatment. The number of cells recovered from
each animal was multiplied by the per-cell LDCL value. Naïve values are represented at
day 0 and arrows indicate intratracheal treatments. Values are means ± SEM.  N=5-9.
*Significantly different from control (p<0.05).
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Figure 20: PMA-stimulated LDCL counts over 20 minutes from BAL cells on Day 3
with specific inhibitors. Cells recovered in the BAL fluid of rats at day 3 following i.t.
instillations of sterile water or AD (6.25 mg/kg) on days 0 and 2 subjected to LDCL with
and without PMA. Group assignments: PMA alone=only PMA; L-NAME= N ω-nitro-L-
arginine methyl ester and PMA; SOD=Superoxide Dismutase and PMA; SOD + L-
NAME=both inhibitors and PMA. Values are ± SEM. N=5-9. *Significantly different
from control (p<0.05). #Significantly different than corresponding PMA alone value
(p<0.05 ).
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Figure 21: NOx (NO2 and NO3) production from BAL cells cultured at Day 3. Rats
were given i.t. AD (6.25 mg/kg) or sterile water on days 0 and 2 and lavaged on day 3.
The BAL cells were then cultured 24 hours, after which the media was assayed for nitrate
(NO3) and nitrite (NO2), collectively referred to as NOx, which are the stable products of
NO in solution. Values are means ± SEM. N=3. *Significantly different from control
(p<0.05).
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Figure 22: Effect of AD on surfactant protein-D levels in serum. Rats were given i.t.
AD (6.25 mg/kg) or an equivalent volume of sterile water on days 0 and 2. Serum was
collected as various time points and assayed for SP-D. Naïve values are represented at
day 0 and arrows indicate intratracheal treatments. Values are means ± SEM. N=5-9.
*Significantly different from control (p<0.05).
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Figure 23: Albumin in the first BAL fraction on day 3 following intratracheal
amiodarone, vehicle, or acidic vehicle treatment on days 0 and 2. Rats were given i.t.
AD (6.25 mg/kg), sterile water, or sterile water adjusted to pH 3.7 with HCl to match the
pH of the amiodarone solution on days 0 and 2.  Rats were lavaged on day 3 and albumin
levels were measured in the first BAL fraction. Values are means ± SEM. N=6-11.
*Significantly different from sterile water control (p<0.05). #Significantly different from
acidic water control.
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Figure 24: Total BAL cells recovered on day 3 following intratracheal amiodarone,
vehicle, or acidic vehicle treatment on days 0 and 2. Rats were given i.t. AD (6.25
mg/kg), sterile water, or sterile water adjusted to pH=3.7 with HCl to match the pH of the
amiodarone solution on days 0 and 2.  Rats were lavaged on day 3 and the BAL cells
were counted and differentiated. Values are means ± SEM. N=6-11. *Significantly
different from sterile water control (p<0.05). #Significantly different from acidic water
control.
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Figure 25: Total alveolar macrophages recovered on day 3 following intratracheal
amiodarone, vehicle, or acidic vehicle treatment on days 0 and 2. Rats were given i.t.
AD (6.25 mg/kg), sterile water, or sterile water adjusted to pH=3.7 with HCl to match the
pH of the amiodarone solution on days 0 and 2.  Rats were lavaged on day 3 and the BAL
cells were counted and differentiated. Values are means ± SEM. N=6-11. *Significantly
different from sterile water control (p<0.05).
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Figure 26: Total neutrophils (PMNs) recovered on day 3 following intratracheal
amiodarone, vehicle, or acidic vehicle treatment on days 0 and 2. Rats were given i.t.
AD (6.25 mg/kg), sterile water, or sterile water adjusted to pH=3.7 with HCl to match the
pH of the amiodarone solution on days 0 and 2.  Rats were lavaged on day 3 and the BAL
cells were counted and differentiated. Values are means ± SEM. N=6-11. *Significantly
different from sterile water control (p<0.05). #Significantly different from acidic water
control.
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Figure 27: Total eosinophils recovered on day 3 following intratracheal amiodarone,
vehicle, or acidic vehicle treatment on days 0 and 2. Rats were given i.t. AD (6.25
mg/kg), sterile water, or sterile water adjusted to pH=3.7 with HCl to match the pH of the
amiodarone solution on days 0 and 2.  Rats were lavaged on day 3 and the BAL cells
were counted and differentiated. Values are means ± SEM. N=6-11. *Significantly
different from sterile water control (p<0.05). #Significantly different from acidic water
control.
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Figure 28A: Non-LPS-stimulated NOx production from cultured BAL cells lavaged
at various time-points following intratracheal instillation of amiodarone or vehicle.
Rats were given either a single i.t. dose of AD (6.25 mg/kg) or sterile water and lavaged
at 15 minutes, 1 hour, 3 hours, or given the i.t. doses at day 0 and 2 and lavaged on day 3.
The BAL cells were then cultured (without LPS addition) 24 hours, after which the media
was assayed for nitrate (NO3) and nitrite (NO2), collectively referred to as NOx, which
are the stable products of NO in solution. Values are means ± SEM. N=3-9. No
significant differences from control (p<0.05).
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Figure 28B: LPS-stimulated NOx production from cultured BAL cells lavaged at
various time-points following intratracheal instillation of amiodarone or vehicle.
Rats were given either a single i.t. dose of AD (6.25 mg/kg) or sterile water and lavaged
at 15 minutes, 1 hour, 3 hours, or given the i.t. doses at day 0 and 2 and lavaged on day 3.
The BAL cells were then cultured (with LPS added) 24 hours, after which the media was
assayed for nitrate (NO3) and nitrite (NO2), collectively referred to as NOx, which are the
stable products of NO in solution. Values are means ± SEM. N=3-9. No significant
differences from control (p<0.05).
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Figure 29A: Non-LPS-stimulated TNF-α production from cultured BAL cells
lavaged at various time-points following intratracheal instillation of amiodarone or
vehicle. Rats were given either a single i.t. dose of AD (6.25 mg/kg) or sterile water and
lavaged at 1 hour or 3 hours, or given the i.t. doses at day 0 and 2 and lavaged on day 3.
The BAL cells were then cultured 24 hours without LPS, after which the media was
assayed for TNF-α. Values are means ± SEM. N=3-4. No significant differences from
control (p<0.05).
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Figure 29B: LPS-stimulated TNF-α production from cultured BAL cells lavaged at
various time-points following intratracheal instillation of amiodarone or vehicle.
Rats were given either a single i.t. dose of AD (6.25 mg/kg) or sterile water and lavaged
at 1 hour or 3 hours, or given the i.t. doses at day 0 and 2 and lavaged on day 3. The BAL
cells were then cultured 24 hours with LPS, after which the spent media was assayed for
TNF-α. Values are means ± SEM. N=3-4. *Significantly different from control (p<0.05).
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Figure 30: TNF-α levels in the first BAL fraction at various time-points following
instillation of amiodarone or vehicle. Rats were given either a single i.t. dose of AD
(6.25 mg/kg) or sterile water and lavaged at 15 minutes, 1 hour, 3 hours, or given the i.t.
doses at day 0 and 2 and lavaged on day 3. TNF-α levels were determined in the first
BAL fraction. Values are means ± SEM. N=2-4. *Significantly different from control
(p<0.05).
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Figure 31: IL-1β production from cultured BAL cells recovered by lavage 3 hours
following intratracheal amiodarone or vehicle treatment.  Rats were given a single i.t.
dose of AD (6.25 mg/kg) or sterile water and subjected to BAL 3 hours later. BAL cells
were then cultured 24 hours with and without LPS. IL-1β levels were determined in the
culture media. Values are means ± SEM. N=4. *Significantly different from control with
LPS (p<0.05).
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Figure 32A: IL-6 production from BAL cells recovered by lavage 15 minutes
following i.t. instillation of amiodarone or vehicle and cultured 24 hours. Rats were
given a single i.t. dose of AD (6.25 mg/kg) or sterile water and subjected to BAL 15
minutes later. BAL cells were then cultured 24 hours with and without LPS. IL-6 levels
were determined in the culture media. Values are means ± SEM. N=2-4. No significant
differences from control (p<0.05).
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Figure 32B: IL-6 production from BAL cells recovered by lavage on day 3 following
i.t. instillation of amiodarone or vehicle and cultured 24 hours. Rats were given i.t.
AD (6.25 mg/kg) or sterile water on days 0 and 2 and subjected to BAL on day 3. BAL
cells were then cultured 24 hours with and without LPS. IL-6 levels were determined in
the culture media. Values are means ± SEM. N=2-4. No significant differences from
control (p<0.05).
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Figure 33A: IL-10 production from BAL cells recovered by lavage 15 minutes
following i.t. instillation of amiodarone or vehicle and cultured 24 hours. Rats were
given a single i.t. dose of AD (6.25 mg/kg) or sterile water and subjected to BAL 15
minutes later. BAL cells were then cultured 24 hours with and without LPS. IL-10 levels
were determined in the culture media. Values are means ± SEM. N=2-4. No significant
differences from control (p<0.05).
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Figure 33B: IL-10 production from BAL cells recovered by lavage on day 3
following i.t. instillation of amiodarone or vehicle and cultured 24 hours. Rats were
given i.t. AD (6.25 mg/kg) or sterile water on days 0 and 2 and subjected to BAL on day
3. BAL cells were then cultured 24 hours with and without LPS. IL-10 levels were
determined in the culture media. Values are means ± SEM. N=2-4. No significant
differences from control (p<0.05).
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Figure 34: Albumin in the first BAL fraction at various time-points following
intratracheal amiodarone or vehicle treatment. Rats were either given a single i.t.
dose of AD (6.25 mg/kg) or sterile water and subjected to BAL after 15 minutes, 1 hour,
or 3 hours, or were given i.t. doses of AD or water on days 0 and 2 and subjected to BAL
on day 3.  Albumin was measured in the first BAL fraction. Naïve values are represented
at day 0. Values are mean ± SEM. N=5-9. *Significantly different from control (p<0.05).
#Significantly different than AD-treated day 3 level (p<0.05).
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Figure 35: LDH Activity in the first BAL fraction at two time-points following
intratracheal amiodarone or vehicle treatment. Rats were either given a single i.t.
dose of AD (6.25 mg/kg) or sterile water and subjected to BAL after 15 minutes or given
i.t. doses of AD or water on days 0 and 2 and subjected to BAL on day 3.  LDH activity
was measured in the first BAL fraction. Values are mean ± SEM. N=5-6. *Significantly
different from control (p<0.05). #Significantly different than AD-treated day 3 level
(p<0.05).
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Figure 36A: Effect of AD, citrate buffer, or HCl on albumin in the first BAL
fraction at 15 min. Rats were instilled intratracheally with AD (6.25 mg/kg) or an
equivalent volume of citrate buffer (pH 3.7; equal to AD solution), HCl (equimolar
concentration to AD-HCl), or sterile water and albumin was measured in the first BAL
fraction. Values are means ± SEM. N=4-5. *Significantly different from water (p<0.05).
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Figure 36B: Effect of AD, citrate buffer, or HCl on LDH activity in the first BAL
fraction at 15 min. Rats were instilled intratracheally with AD (6.25 mg/kg) or an
equivalent volume of citrate buffer (pH 3.7; equal to AD solution), HCl (equimolar
concentration to AD-HCl), or sterile water and LDH activity was measured in the first
BAL fraction. Values are means ± SEM. N=3-5. *Significantly different from water
(p<0.05).
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Figure 37A: Representative images obtained by LSCM of the effect of AD on
cellular viability in situ at 15 min.  Rats were given a single i.t. dose of AD (6.25
mg/kg) or sterile water and in situ viability was examined in lung tissue with LSCM at 15
min.  Cells that have lost membrane integrity stain ethidium-positive and are displayed as
red. Cells that have not taken up ethidium are stained green with Yo-Pro-1. Cells with
both stains present may appear yellow and are also ethidium-positive. Scale bars indicate
size in µm.
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Figure 37B: Representative images obtained by LSCM of the effect of AD on
cellular viability in situ at 3 hours.  Rats were given a single i.t. dose of AD (6.25
mg/kg) or sterile water and in situ viability was examined in lung tissue with LSCM at 3
hours.  Cells that have lost membrane integrity stain ethidium-positive and are displayed
as red. Cells that have not taken up ethidium are stained green with Yo-Pro-1. Cells with
both stains present may appear yellow and are also ethidium-positive. Scale bars indicate
size in µm.
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Figure 37C: Representative images obtained by LSCM of the effect of AD on
cellular viability in situ at day 3.  Rats were given i.t. AD (6.25 mg/kg) or sterile water
on days 0 and 2 and in situ viability was examined in lung tissue with LSCM at day 3.
Cells that have lost membrane integrity stain ethidium-positive and are displayed as red.
Cells that have not taken up ethidium are stained green with Yo-Pro-1. Cells with both
stains present may appear yellow and are also ethidium-positive. Scale bars indicate size
in µm.
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Figure 38: Representative micrographs of thin sections obtained by LSCM for in
situ quantification of the effect of AD on cellular viability at 15 min. Rats were
instilled intratracheally with AD (6.25 mg/kg) or sterile water and in situ cellular viability
was determined at 15 min. Cells that have lost membrane integrity stain ethidium-
positive and are displayed as red. Cells that have not taken up ethidium are stained green
with Yo-Pro-1. Cells with both stains may appear yellow and are also ethidium-positive.
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Figure 39A: Effect of AD on ethidium staining of airway and parenchymal cells at
15 min. Rats were instilled with i.t. AD (6.25 mg/kg) or sterile water and the number and
location of ethidium-positive cells/field was determined. Values are means ± SEM.
N=200-250 fields per treatment group. *Significantly different from water (p<0.05).
#Significantly different from AD parenchyma (p<0.05).
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Figure 39B: Overall total cells, total airway cells, and total parenchymal cells per
field at 15 min. Rats were instilled with i.t. AD (6.25 mg/kg) or sterile water and the
number and location of total (ethidium-positive and Yo-Pro-1-positive) cells/field was
determined. Values are means ± SEM. N=200-250 fields per treatment group. No
significant differences were found (p<0.05).
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Figure 40: Representative micrographs of thin sections obtained by LSCM for in
situ quantification of the effect of AD on cellular viability at day 3. Rats were instilled
intratracheally with AD (6.25 mg/kg) or sterile water and on days 0 and 2 and in situ
cellular viability was determined at day 3. Cells that have lost membrane integrity stain
ethidium-positive and are displayed as red. Cells that have not taken up ethidium are
stained green with Yo-Pro-1. Cells with both stains may appear yellow and are also
ethidium-positive.
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Figure 41A: Effect of AD on ethidium staining of airway and parenchymal cells at
day 3. Rats were instilled with i.t. AD (6.25 mg/kg) or sterile water on days 0 and 2 and
the number and location of ethidium-positive cells/field was determined. Values are
means ± SEM. N=150-250 fields per treatment group. *Significantly different from water
parenchyma (p<0.05).
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Figure 41B: Overall total cells, total airway cells, and total parenchymal cells per
field at day 3. Rats were instilled with i.t. AD (6.25 mg/kg) or sterile water on days 0 and
2 and the number and location of total (ethidium-positive and Yo-Pro-1-positive)
cells/field was determined. Values are means ± SEM. N=150-250 fields per treatment
group. No significant differences were found (p<0.05).
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Figure 42: ESR spectra of AD solution without spin-trapping. A) AD (25 mg/mL) in
water without DMPO showing the presence of a carbon-based radical (1) and an
unknown radical (2). B) AD (100 mg/mL) in water without DMPO showing the
elimination of radical signal with increased AD concentration. Arrow indicates 15 Gauss
width and direction of scanning.
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Figure 43: ESR spectrum of AD powder.  Spectra of dry AD powder showing the
presence of a carbon-based radical. Arrow indicates 15 Gauss width and direction of
scanning.
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Figure 44: Time course of AD-induced DMPO peak formation in water; effects of
inhibitors and exogenous chemicals.  DMPO was added to AD (3.125 mg/mL) in water
to trap hydroxyl radicals with and without inhibitors and exogenous chemicals. The
samples were analyzed at various time-points with ESR, and the two center peaks
(doublets) of the hydroxyl-DMPO signal were measured and averaged for each spectrum.
Inhibitors and chemicals (and final concentrations) used were: DMPO (.33 M);
superoxide dismutase (SOD; 5 mg/mL); catalase (Cat; 5000 U/L); deferoxamine (Def; 20
mM); formate (500 mM).
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Figure 45A: Time course of AD-induced DMPO peak formation in PBS; effects of
inhibitors and exogenous chemicals.  DMPO was added to AD (3.125 mg/mL) in PBS
to trap hydroxyl radicals with and without inhibitors and exogenous chemicals. The
samples were analyzed at various time-points with ESR, and the two center peaks
(doublets) of the hydroxyl-DMPO signal were measured and averaged for each spectrum.
Inhibitors and chemicals (and final concentrations) used were: DMPO (.33 M);
superoxide dismutase (SOD; 5 mg/mL); catalase (Cat; 5000 U/L); deferoxamine (Def; 20
mM); formate (500 mM); FeSO4 (Fe
++; 1 mM); H2O2 (10 mM).
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Figure 45B: Final spectra in the time course of AD-induced DMPO peak formation
in PBS; effects of inhibitors and exogenous chemicals.  DMPO was added to AD
(3.125 mg/mL) in PBS to trap hydroxyl radicals with and without inhibitors and
exogenous chemicals. The final spectrum of each sample is shown. Inhibitors and
chemicals (and final concentrations) used were: DMPO (.33 M); superoxide dismutase
(SOD; 5 mg/mL); catalase (Cat; 5000 U/L); deferoxamine (Def; 20 mM); formate (500
mM); H2O2 (10 mM).
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Figure 46: Time course of AD-induced DMPO peak formation in PBS; effect of
heat-inactivation of inhibitor enzymes.  DMPO was added to AD (3.125 mg/mL) in
PBS to trap hydroxyl radicals with and without enzymes. The samples were analyzed at
various time-points with ESR, and the two center peaks (doublets) of the hydroxyl-
DMPO signal were measured and averaged for each spectrum. Enzymes indicated were
heat-inactivated by being placed in a boiling water bath for 10-min. Enzymes (and final
concentrations) used were: DMPO (.33 M); superoxide dismutase (SOD; 5 mg/mL);
catalase (Cat; 5000 U/L); heat-inactivated SOD (HI SOD; 5 mg/mL); heat-inactivated
Cat (HI Cat; 5000 U/L).
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Figure 47: Time course of AD-induced DMPO peak formation in PBS; effects of
thiol antioxidants.  DMPO was added to AD (3.125 mg/mL; 4.5 mM) in PBS to trap
hydroxyl radicals with and without thiol antioxidants. The samples were analyzed at
various time-points with ESR, and the two center peaks (doublets) of the hydroxyl-
DMPO signal were measured and averaged for each spectrum. Antioxidants and
chemicals (and final concentrations) used were: DMPO (.33 M); N-acetyl cysteine (NAC;
9.0 mM); reduced glutathione (GSH; 9.0 mM).
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Figure 48: ESR spectra of AD solution in chloroform with spin-trapping at 3 min.
A) AD (3.125 mg/mL) in chloroform with DMPO showing the presence an undetermined
radical, presumably an AD radical. B) AD (3.125 mg/mL; 4.5 mM) in chloroform with
NAC (9.0 mM) showing the presence of an N-acetyl cystyl radical splitting with the
undetermined radical signal. Arrow indicates 15 Gauss width and direction of scanning.
103
Figure 49: Effect of AD concentration on hydroxyl radical production at 30 min. AD
at various concentrations was incubated with DMPO for 30 min before being analyzed by
ESR. The two center peaks (doublets) of the hydroxyl-DMPO signal were measured and
averaged for each spectrum.
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Figure 50: ESR spectra of AD solution in water with spin-trapping at 30 min.;
effects of UV irradiation and antioxidants. A) AD (3.125 mg/mL) in water with
DMPO at 30 min showing the presence of hydroxyl radical. B) AD (3.125 mg/mL) in
water with DMPO at 30 min following UV irradiation during the first 10 min of
incubation. C) AD (3.125 mg/mL; 4.5 mM) with DMPO, Trolox (45 mM), and ascorbate
(22.5 mM) showing the elimination of radical signal. Arrow indicates 15 Gauss width
and direction of scanning.
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Figure 51A: Effect of AD with and without antioxidants on albumin in the first BAL
fraction at 15 min.  Rats were instilled intratracheally with AD (6.25 mg/kg) with or
without antioxidants (AAs; Trolox [45 mM] and ascorbate [22.5 mM] in water) or an
equivalent volume of the antioxidants alone or sterile water. Albumin was measured in
the first BAL fraction at 15 min. Values are means ± SEM. N=4-6. *Significantly
different from water (p<0.05). #Significantly different from AD.
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Figure 51B: Effect of AD with and without antioxidants on LDH activity in the first
BAL fraction at 15 min. Rats were instilled intratracheally with AD (6.25 mg/kg) with
or without antioxidants (AAs; Trolox [45 mM] and ascorbate [22.5 mM] in water) or an
equivalent volume of the antioxidants alone or sterile water and LDH activity was
measured in the first BAL fraction. Values are means ± SEM. N=4-6. *Significantly
different from water (p<0.05).
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Figure 52A: Positive-ion electrospray mass spectra of AD in methanol and water. A)
Spectrum of AD (4.5 µM diluted from 4.5 mM) dissolved in methanol showing parent-
compound peaks. B) Spectrum of AD (4.5 µM diluted from 4.5 mM) dissolved in water
showing parent compound peaks and peak(s) of possible breakdown products. No
evidence for a mono-deiodination of AD [~518 Da] is shown, but a possible di-
deiodinated AD [~393 Da] is shown.
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Figure 52B: Negative-ion electrospray mass spectra of AD in methanol and water.
A) Spectrum of AD (4.5 µM diluted from 4.5 mM) dissolved in methanol showing no
evidence of deiodination (I- [127 Da], I2 [254 Da], or I3 [381 Da]). B) Spectrum of AD
(4.5 µM diluted from 4.5 mM) dissolved in water showing no evidence of deiodination (I,
I2, or I3). The peaks at 167.8 and 212.6 Da in both negative-ion spectra are known
contaminants of the analysis system.
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Discussion
The overall objective of this research project was to develop and characterize a rat
model of AIPT. It was anticipated that the study of such a model would aid in identifying
the underlying causes of AIPT.  Once the mechanisms of disease development are
elucidated, specific treatments directed against these mechanisms could be developed.
To accomplish this goal, a rat model for AIPT was developed and characterized.  This
model incorporated the more damaging aspects of AIPT of inflammation and fibrosis.
However, the early damage to the lungs done by the drug solution directly does not
mimic the pathology of AIPT in humans.
The project may be divided into three main objectives.  The first was to examine
existing animal models in order to identify the most useful, or if none were adequate, to
develop one that was.  The second was to characterize the chosen model, with attention to
the endpoints of inflammation and fibrosis, as well as possible mechanisms that may
cause or contribute to the toxicity.  The third was to examine the initial events that occur
soon after the drug is administered, focusing primarily on the temporal relationships
between the production of inflammatory cytokines, the appearance of inflammatory cells,
and the initial damage to the alveolar-capillary barrier and cellular death.  The direct role
of AD in this damage and cellular death was also examined, as were properties of the
drug that could contribute to toxicity.
As previously stated, two primary routes of administration exist in the literature
for animal models of AIPT.  Oral dosing of animals leads to a marked phospholipidosis
in lung cells and tissue, but does not produce a consistent inflammatory or fibrotic
response.  Conversely, i.t. dosing of animals produces an initial inflammation
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subsequently followed by fibrosis without producing the drug accumulation and
phospholipidosis characteristic of the oral route.  Thus the i.t. route has become favored
in studies that examine the inflammatory and/or fibrotic aspects of AIPT, which are the
aspects of the toxicity that are more serious and potentially fatal.  The i.t. AD model was
based on the development of an i.t. model of bleomycin-induced pulmonary fibrosis,
even though the pathology between oral and i.t. bleomycin-induced fibrosis were
subsequently found to be different.  The use of the i.t. AD model has continued because
of the lack of inflammation and fibrosis in oral animal models of AIPT.
Much of the research thus far has utilized hamsters as the test animal.  Models
that involve the i.t. dosing of hamsters with AD have been characterized with regards to
the inflammatory and fibrotic responses.  However, attempts to elucidate the signaling
mechanisms involved may have been hindered by the lack of widely available molecular
tools and reagents for hamsters.  Researchers would have to generate specific antibodies
against hamster proteins and develop their own ELISAs for each signaling protein they
were interested in, a process that is time-consuming and labor-intensive, and still carries a
risk of failure.  However, many of these reagents are commercially available for rats,
making rats a more attractive species for the study of signaling molecules.  While it has
been reported that an i.t. dose of AD leads to fibrosis in rats (Reinhart et al, 1996), little
information exists about the development of inflammation or any other early events in the
progression of the toxicity.  Thus the potential exists for a rat model of AIPT to be
helpful in elucidating the events that occur in the development of the toxicity as well as to
identify the signaling molecules directing the responses.
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The first objective was to define the animal model and select the dosing protocol
to be subsequently fully characterized.  To accomplish this, rats were treated either orally
and intratracheally with AD so a comparison of responses could be made.  As expected,
the oral treatment led to phospholipidosis and an accumulation of AD and dAD in BAL
cells without producing significant inflammation when dosed 7 or 14 days.  A single i.t.
dose of AD did lead to inflammation at day 5 without phospholipidosis or drug
accumulation.  Furthermore, the cells recovered on day 5 from i.t. AD-treated rats
produced more NO in culture and more LDCL counts over 20 minutes than cells from
control rats.  Cells from rats treated orally for 7 days did not produce more NO or LDCL
than controls, indicating that the cells from the i.t. AD-treated rats were activated to
produce more oxidants while cells from oral-AD-treated rats were not primed.  Because
the oral treatment was reported not to lead to fibrosis (confirmed later in this study) and
the i.t. treatment did, these findings were consistent with the hypothesis that i.t. treatment
activates the cells to produce more oxidants, possibly causing lung damage and
subsequent fibrosis, while the oral treatment does not activate cells.  Thus the i.t. model
was further examined as a potential model of AIPT to fully characterize.
Amiodarone is not extremely water-soluble, and will not dissolve in an ionic
solution such as saline at neutral pH.  It will, however, dissolve in water when heated to
about 70oC, but will immediately precipitate if saline is added in an attempt to make the
solution physiological.  While the report of fibrosis in rats used AD dissolved in water, a
previous study in the hamster model used AD suspended in saline for instillations (Blake
and Reasor, 1995a).  An experiment to compare cellular activation via LDCL using AD
either dissolved in water or suspended in saline revealed that AD in water stimulated the
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cells more than AD in saline.  AD in water may be able to penetrate cells more readily
than AD in a particulate form, thus activating the cells more, or AD in solution may be
more reactive if participating in radical reactions.  Because of this finding, and to avoid
any complications of instilling AD in particulate form in saline, AD dissolved in water
was chosen as the preparation for subsequent intratracheal dosing.  However, the ultimate
state of AD once it is in the ionic but surfactant-rich fluid lining of the lungs is unknown.
Since it was desirable that the model included a fibrotic endpoint, studies to
confirm the fibrosis reported earlier by this dosing technique (Reinhart et al, 1996) were
performed.  Surprisingly, the single i.t. dose of AD did not lead to a consistent elevation
of right-lung hydroxyproline levels of fibrosis histopathologically.  To achieve a
significant increase in hydroxyproline following AD treatment, a second dose of AD or
control vehicle was added to the regimen.  To identify the appropriate time to give the
second dose, experiments comparing hydroxyproline levels at day 28 when the drug was
given at days 0 and 2 or at days 0 and 7, the latter protocol previously reported in a
hamster model (Blake and Reasor, 1995b).  The protocol with doses at days 0 and 2 was
more fibrogenic than that with day 0 and 7 dosing, meaning the day 0 and 2 protocol
would be adopted for subsequent studies with AD.  An experiment to identify the proper
time-point for analysis of fibrosis revealed no differences between AD-induced
hydroxyproline increases at 4 or 6 weeks; therefore the 4 week (28 day) time-point was
chosen for any subsequent fibrosis analyses.
In a final attempt to elevate right-lung hydroxyproline levels even further, another
dosing protocol was implemented combining both the i.t. and oral dosings in the same
animals.  This protocol has not been previously reported in the literature.  Two groups of
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animals were treated with two different protocols.  The first group, referred to as
concurrent, were administered both the first oral and first i.t. dose on day 0, and
subsequently received the second i.t. dose on day 2 and daily oral doses through the
entire treatment period.  The second group, referred to as orally pretreated, was treated
orally with AD or vehicle for 7 days before the first of two i.t. doses were given, and
daily oral doses were given until analysis at day 28.  Controls were weight-matched to the
orally treated rats by withholding food to eliminate effects of body weight and size on
right-lung hydroxyproline levels.  Groups of i.t.-only and oral-only treatments were also
included for comparison.  The concurrent drug treatment failed to elevate hydroxyproline
levels above those of the i.t.-only group, and in fact, the orally pretreated group was
protected from a significant increase in hydroxyproline levels.  This may be due to the
presence of phospholipidosis that is present in one week as demonstrated by the previous
studies using oral AD.  The lipid material in the alveolar region may act as a sink for the
relatively small amounts of drug instilled intratracheally, protecting the cells from
activation and/or the lungs from direct damage.  This lipid material could protect from
radical-induced damage, whether the radicals are produced from activated cells or
directly from the drug molecule.  Since the oral treatment complicated the development
of fibrosis without adding to the levels of hydroxyproline measured, the i.t.-only protocol
was chosen to be characterized more thoroughly with regards to the development of
inflammation, lung damage, and fibrosis.
The second objective of the study was to characterize the response of rats to day 0
and 2 i.t. doses of AD or water.  This protocol produced a significant fibrosis as analyzed
by three separate techniques.  Traditional analysis of fibrosis usually includes a
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biochemical analysis of fibrosis and/or a separate histopathologic analysis.  There are
advantages and disadvantages to each technique.  Biochemical analysis allows
quantification of the level of fibrosis, but because the lung tissue is completely digested
during the analysis, no information can be gathered about the location of type of fibrosis
involved.  This technique also may not detect focal fibrosis that does not significantly add
to the total lung hydroxyproline levels.  Conversely, histopathological analysis allows
localization and characterization of fibrosis, but quantitation with this technique is
subjective at best.  An attempt was made to use LSCM with lucifer yellow staining to
both quantitate connective tissue and analyze the location and type of fibrosis.  This
technique may be useful in the examination of lung biopsy tissue, or any application
where the amount of lung tissue for analysis is limited, for fibrosis.  The increase in lung
tissue area found in this study correlated with in increase in the amount of lung collagen,
as was probably directly related.  However, there are instances when septal thickening
may occur in which fibrosis is not occurring, such as pulmonary edema and interstitial
inflammation.  Lucifer Yellow preferentially stains collagen, and therefore much of the
area with edema (and therefore lightly stained) can be thresholded out.  Masking tools
exist in the software to remove inflammatory cells from quantitation, although this
technique was not necessary in this study.
To examine the early responses involved in this model, rats were dosed
intratracheally with either AD in sterile water (6.25 mg/mg in a 3.125 mg/mL solution) or
the sterile water vehicle and were lavaged at various time-points.  Specifically, damage to
the alveolar-capillary barrier as well as the number, type, and level of activation of BAL
cells were examined at days 3, 5, 6, 7, and 10.  The elevated albumin levels found in the
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first BAL fraction indicated an early damage to the alveolar-capillary barrier, allowing
the protein from the blood to cross into the alveolar space.  The integrity of the relatively
delicate barrier between the air in the blood in the alveolar region of the lungs is a good
indicator of lung damage.  Damage is most prominent at day 3, and resolves quickly
thereafter.  Therefore, in this model, the development of fibrosis was associated with an
early and transient damage to the alveolar-capillary barrier.
The total number of cells recovered by BAL from AD-treated rats was
significantly elevated on days 3 and 5.  This indicates a cellular response to the AD
administration.  When the cells were differentiated, most were found to be alveolar
macrophages, which were also significantly elevated in number on days 3 and 5.  The
number of alveolar macrophages can be increased by recruitment from the surrounding
tissue as well as from monocytes recruited from the blood (Sibille and Reynolds, 1990).
Stimulated macrophages can play an instrumental role in directing an inflammatory
reaction by releasing chemical mediators to direct the recruitment of inflammatory cells
as well as releasing oxidants as part of the host-defense system (Laskin and Pendino,
1995).  There is evidence that inflammatory cells are indeed recruited to the lungs after
AD administration, as the number of polymorphonuclear leukocytes (PMNs) was
increased at day 3.  PMNs are important in the inflammatory response in that they can
release a variety of inflammatory mediators as well as oxidant species when recruited and
activated.  PMNs are recruited in various types of inflammatory reactions (Sibille and
Reynolds, 1990).
The eosinophil is another type of inflammatory cell recruited to the lung after AD
administration.  Eosinophils are more often recruited during inflammatory reactions
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involving immune reactions, possibly implicating an immunological component to AIPT
in this model.  Elevated eosinophils have also been reported in a hamster model for AIPT
(Blake and Reasor, 1995a) and in the lungs of some human patients with AIPT (Akoun et
al., 1991).  The basis for eosinophil recruitment in this model is not clear, although
proteins altered by AD could be perceived as foreign and initiate an immune response.
Eosinophils can participate in inflammatory reactions by releasing damaging enzymes
and oxidant species (Giembycz and Lindsay, 1999).
To assess the capacity for activation of the cells recovered by BAL, the cells were
subjected to LDCL with and without PMA stimulation.  PMA-stimulated BAL cells from
AD-treated rats produced significantly more LDCL counts over 20 minutes than PMA-
stimulated cells from control animals at day 3, indicating more oxidants were being
produced.  This indicates that the BAL cells from AD-treated rats can be activated to
produce more oxidant species on a per-cell basis on day 3 than BAL cells from control
animals.  Since the total cell number was also elevated at day 3, the potential total oxidant
burden was calculated by multiplying the PMA-stimulated LDCL counts, which were on
a per-cell basis, by the total number of BAL cells recovered.  Thus, on day 3, there is a
much greater potential oxidant burden on the lungs of AD-treated animals than in the
lungs of control animals.
In an attempt to identify the oxidant species involved in the LDCL response at
day 3, specific inhibitors were utilized.  L-NAME was used as an inhibitor of NO
production while SOD was used as a scavenger of superoxide radicals.  L-NAME alone
significantly inhibited LDCL production from BAL cells from AD-treated rats. SOD also
significantly inhibited light production presumably by scavenging superoxide anions
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produced by BAL cells. Therefore, much of the light response was dependent on
superoxide production.  Even though SOD inhibited more light than L-NAME, L-NAME
is a charged molecule that may not penetrate the cell membrane well enough to reach
maximally effective inhibitory concentrations in the cytosol.  Furthermore, when SOD
and L-NAME were combined, light production from PMA-stimulated BAL cells was
inhibited to the level of non-PMA-stimulated cells.  Increased NO production was also
shown from cells cultured from AD-treated animals.  Since superoxide and NO readily
combine to form the powerful oxidant peroxynitrite, it is possible that peroxynitrite
production is increased from BAL cells from AD-treated rats.  The conclusion from these
experiments was that AD administration might lead to elevated oxidant stress in the lungs
resulting from elevated production of oxidant species by an increased number of cells in
the lungs soon after the drug doses.  This may cause damage to the lung tissue that, when
subsequently repaired, leads to increased collagen deposition and pulmonary fibrosis.
However, the direct role of the drug in the early damage had not yet been explored.
Another goal of the study was to identify a biomarker that could easily be
measured in the serum and could potentially aid in the diagnosis of AIPT. If applicable to
humans, it would be important that this material could be obtained easily and monitored
serially from the beginning of AD treatment. Also, it should correlate with the early
aspects of the toxicity, such as pulmonary inflammation, so that a proper diagnosis can be
made and the patient treated before the onset of irreversible and potentially fatal
pulmonary fibrosis. It was found that serum levels of SP-D, a surfactant-associated
protein, were elevated during the inflammatory stage of the response and through day 7.
Therefore, SP-D levels in humans may serve as a useful marker for the onset of AIPT and
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may aid in its initial diagnosis, which is often difficult (Martin and Rosenow, 1988b).
Currently diagnosis is made using non-specific symptoms and chest imaging without
specific diagnostic features, and can be complicated by the presence of other disorders
(Martin and Rosenow, 1988b; Butler and Smathers, 1985; Delany et al., 1993).
Substances previously proposed as biomarkers for AIPT may lack pulmonary specificity.
SP-D may prove useful as an indicator of the lung-specific damage that occurs early in
the development of AIPT. SP-D levels would need to be measured in patients taking
amiodarone over time, and if increased would provide a signal that damage is occurring.
Research to characterize changes in serum SP-D levels is required before it could be
adopted as a biomarker in humans. However, serum SP-D increases have been correlated
with the development of adult respiratory distress syndrome (ARDS) (Greene et al.,
1999), pulmonary alveolar proteinosis (PAP), idiopathic pulmonary fibrosis (IPF), and
interstitial pneumonia with collagen vascular diseases (IPCD) in humans (Kuroki et al.,
1998). Therefore there is potential for elevated serum SP-D levels in patients developing
AIPT.  However, because of the massive damage that occurs to the alveolar-capillary
barrier in this model, the clinical relevance of these findings is unknown.  The monitoring
of SP-D levels in patients taking amiodarone is necessary to determine its usefulness as a
biomarker for AIPT.
To elucidate the effects that the low pH of the AD solution may have been having
on the cellular differentials and albumin leakage at day 3, sterile water adjusted to the
same pH as AD solution with HCl was instilled on days 0 and 2.  The BAL results on day
3 were compared to animals treated with AD and non-adjusted sterile water (the normal
control).  “Acidic water” (same pH as AD solution) did not induced increases in total
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cells, macrophages, PMNs, or eosinophils that is seen with the AD treatment.  Acidic
water also did not elevate albumin levels in the first BAL fraction, indicating those
responses were drug-specific.
The third objective was to examine the initial events that occur soon after the drug
is administered, focusing primarily on the temporal relationships between the production
of inflammatory cytokines, the appearance of inflammatory cells, and the direct role of
the drug in the initial damage to the alveolar-capillary barrier.  By examining both ex vivo
cytokine production and cytokine levels in the first BAL fraction, it was apparent that the
inflammation resulting from i.t. AD dosing did not follow the traditional pattern of an
initial increase in TNF-α, followed by and increase in IL-1β.  Instead, TNF-α production
was inhibited after AD administration both in cells cultured from AD-treated rats and
directly in the lavage fluid of AD-treated rats.  While the inhibition of TNF-α production
at the early time-points may be due to the killing of the cells that produce it, the findings
of inhibited LPS-stimulated TNF-α production at day 3 are free from viability issues
(viability of cells recovered at day 3 is >90%).  This implicates an inhibition of the TNF-
α production process. This is in agreement with a study of human peripheral blood
monocytes which showed a decrease in TNF-α production following treatment with AD
(Matsumori et al., 1997).  It is likely that the inhibition of TNF-α production following
i.t. AD is not permanent, however.  A study (Reinhart and Gairola, 1997) in which rats
were subjected to a single i.t. dose of AD (6.25 mg/kg) or water and then lavaged at 1, 3,
or 6 weeks afterwards revealed that cultured BAL cells from AD-treated rats produced
significantly more TNF-α than cells from control rats at the 3- and 6-week time points,
120
but not at the 1 week time-point.  Thus TNF-α may play a role in the development of
pulmonary fibrosis seen at the 6-week time point in that study.
In an attempt to identify any other cytokines that may be have a role in AD-
induced inflammation, IL-1β production was also analyzed from cultured BAL cells at 3
hours post-i.t.  LPS-stimulated IL-1β levels were significantly decreased in the media of
cells from AD-treated animals.  This finding is consistent with the hypothesis that IL-1β
levels are dependent in the initial increase of TNF-α.  Without the TNF-α rise,
production of IL-1β is not stimulated.  It could also be an effect of the mortality rate of
the BAL cells at this time-point.  IL-6 production was examined to determine if a
cytokine involved in the specific immune response was elevated following AD treatment.
However, no changes were found in IL-6 production after AD treatment.  The same is
true for IL-10 production, an anti-inflammatory cytokine.  However, the role of cytokines
in the AD-induced inflammation became much less significant when it became apparent
that the drug solution itself was causing massive damage to the lungs as early as 15 min.
The subsequent cellular responses were probably a non-specific reaction to the damage,
with activated phagocytes engulfing cellular debris.  The presence of the eosinophils still
hint at an immune response in the lungs following AD treatment, possibly through AD-
protein hapten formation.  However, the relatively low number of recruited eosinophils
compared to macrophages suggests a very small role any immunological mechanisms
may be having in the recruitment of cells in this model.
Ethidium homodimer is a vital stain; it cannot cross intact cell membranes due to
its positive charge. However, when cell membranes are disrupted, as in significant
membrane damage or cell death, the ethidium homodimer is able to enter the cell,
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intercalate in the DNA, and fluoresce.  The use of LSCM to examine in situ viability
found focal areas of massive damage soon after i.t. AD, as well as relatively undamaged
areas.  These differences probably reflect the drug distribution following i.t.
administration.
Because substantial ethidium staining and elevated albumin and LDH levels in the
first BAL fraction from AD-treated rats were present as early as 15 min, this time-point
was chosen for subsequent characterization of the direct effect of the drug solution in the
toxicity.  To assess the role of hydrogen ions in the AD solution (3.125 mg/mL; 4.5 mM;
pH 3.7) in the toxicity at 15 min, citrate buffer (pH 3.7) and HCl (4.5 mM; pH 2.5) were
used as control solutions.  Neither acidic control significantly elevated albumin or LDH
activity in the first BAL fraction.  Analysis of ethidium staining in an animal treated with
HCl (4.5 mM) also revealed no qualitative differences from water control.  Therefore the
hydrogen ions in the AD solution do not appear to be the cause of the damage seen after
i.t. AD administration.
In order to quantitate ethidium staining, thin sections of ethidium-stained tissue
were made 15 min following a single i.t. AD or water administration, or on day 3
following i.t. treatments on days 0 and 2.  Using computer software, the number of
ethidium-positive and total cells/random field were obtained.  By categorizing the field as
either airway or parenchymal tissue, AD-induced damaged was localized.  While both
airways and parenchyma were affected 15 min post-i.t. AD, more airway cells/field were
damaged. This indicated that AD is damaging the epithelial cells lining the airways as a
result of the i.t. route of administration.  This damage is repaired by day 3, either by
replacement or simply removal of the damaged cells by phagocytes.  At day 3 more
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parenchymal cells in AD-treated animals stain ethidium-positive, possibly as a result of
damage from activated inflammatory cells in the alveolar regions, although ethidium
staining in general at day 3 is much less than at 15 min.  This LSCM technique confirms
the findings of the damage indicators that massive damage involving cell death is present
soon after i.t. AD administration.  The localization of damage in the airways suggests that
the damage is much different than the pathology of AIPT in human patients.  Human
patients do not undergo a massive cytotoxic event, but rather progress through a gradual
lung-drug accumulation that leads to inflammation and fibrosis.  The inflammation and
fibrosis observed in this model are most likely direct results of the route of administration
of the AD, and thus are not necessarily relevant to the human condition.
The direct damage caused by AD was surprising because AD was not thought to
be a reactive compound.  Free radical formation had been postulated as being involved in
AD-induced phototoxicity, but studies of the free radical generation by AD involved
irradiating the AD with UV light or ionizing radiation.  Vereckei et al. (1993) speculated
that the deiodination of AD would lead to the formation of a very reactive aryl radical.
Experiments were performed in this study to test that hypothesis using ESR techniques to
examine free radical production in solutions similar to that used to treat animals
intratracheally (3.125 mg/ml; 4.5 mM).  Without DMPO spin trapping, a carbon based
free radical signal was indeed found in AD solution (25 mg/mL).  This signal was
reduced by increased concentration of AD (100 mg/mL), demonstrating possible
autoquenching.  Although AD would most likely need to be in solution to be deiodinated,
a carbon-based free radical signal was also found in the dry AD powder, indicating that
the responsible compound may be present before the drug is in solution.
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By using DMPO as a spin trap, hydroxyl radicals were found in the AD solution (3.125
mg/mL) in water.  Hydroxyl radicals were also trapped when a solution of i.v. AD was
diluted to the same concentration (3.125 mg/mL), despite the fact that it was in solution
for several months prior to analysis in the presence of benzyl alcohol and polysorbate 80,
which were present but diluted during the analysis as well (data not shown).  While
pulmonary toxicity has not been associated with the short-term i.v. AD treatment used in
cardiac emergencies, toxicity could be expected to blood vessels and other organs
following the administration of a free radical producer.  However, the extensive binding
of AD by albumin may serve to protect these tissues from damage, as 5 mg/mL albumin
greatly reduced the hydroxyl signal from AD (data not shown). The finding of hydroxyl
Figure 53: Possible pathways for AD-induced hydroxyl radical formation; the
effects of exogenous enzymes and chemicals.
O2 -O2∙ H2O2 OH∙SOD
Cat
H2O + O2
Fe++AD∙
A)
AD∙+ H2O AD-H + OH∙B)
124
radical implies that a parent compound radical is present, and this radical interacts with
constituents in the solution to produce hydroxyl radicals.  Two possible pathways for
hydroxyl production from molecular oxygen (A) and water (B) are presented in Figure
53.  Experiments were done to determine the pathway of hydroxyl radical formation by
the addition of exogenous chemicals and enzymes to the AD solution.
Hydroxyl production induced by AD (3.125 mg/mL) was first analyzed in water.
If the pathway illustrated by Figure 53(A) is occurring, then SOD may enhance hydroxyl
production, while Cat and Def (an iron chelator) should decrease the signal.  All three
compounds reduced the signal, indicating a non-specific effect of the compounds, or
indicating that another pathway may be partly involved.  Since formate changed the pH
of the solution and changed the trapping efficiency of DMPO, this experiment was
repeated in phosphate-buffered saline to maintain constant pH.  Even though the AD
partly came out of solution, hydroxyl radicals were still produced.  SOD, Cat, Def, and
formate all inhibited the signal without eliminating it, while the addition of exogenous
H2O2 increased the hydroxyl signal.  This finding implies that something is acting as a
transition element, possibly a metal or the AD molecule itself.  By adding Fe++, the
presence of H2O2 in AD solution was expected to be determined.  An increased signal
would indicate that H2O2 was involved.  However, the charged ion forced AD completely
out of solution and eliminated the hydroxyl signal.  Formate caused both a reduction and
a splitting of the hydroxyl signal, indicating that the hydroxyl was free in solution, since
formate itself is a radical and competes for the DMPO.
To determine if the effects of the enzymes in the previous studies were specific
for their actions, or an effect of exogenous protein, they were heat-inactivated and added
125
to the AD solution (3.125 mg/mL) in PBS.  However, the enzymes did not produce the
same inhibition as seen in previous experiments.  Heat-inactivated SOD did inhibit to
about the same level as did normal SOD in previous experiments, but heat inactivated Cat
drastically reduced the signal.  This may have been due to the denatured protein releasing
its active site moiety into solution.  The variable effects of the enzymes preclude
definitive determination of the pathway of hydroxyl formation in solution.  The
incomplete inhibition by Def and Cat in the two previous experiments suggest that
hydroxyl radical may be coming from molecular oxygen as well as direct hydrogen
abstraction from water.  However no measurable oxygen consumption was observed in a
solution of AD (25 mg/mL) in water, indicating that molecular oxygen is not used to a
great extent in this particular solution.
To determine if an aryl radical was present in the AD solution (4.5 mM; 3.125
mg/mL in water), thiol antioxidants were added in an attempt to adduct the aryl radical
and eliminate the hydroxyl signal.  However, more hydroxyl was trapped when either
NAC (9.0 mM) or GSH (9.0 mM) was in the AD solution.  This was not due to either
compound altering the pH of the AD solution.  An animal treated with AD (4.5 mM) and
NAC (22.5 mM) in the same solution suffered hemorrhaging and subsequently died.  To
examine the possible oxidation of NAC, AD (3.125 mg/mL) and DMPO were placed into
chloroform with and without NAC.  Without water present, hydroxyl radicals are not
formed, and the spectrum of the parent radical can be obtained.  A radical signal was
found in the AD solution, presumably the AD radical. The addition of NAC (9.0 mM) to
AD and DMPO in chloroform produced a signal consistent with the field width of an N-
acetyl cystyl radical, although the signal was split by the AD radical signal.  This
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indicated that the NAC was being oxidized into a radical itself, and by interacting with
molecular oxygen or water, producing more hydroxyl radicals.  While the exact nature of
the parent compound radical could not be easily identified, the structure could be inferred
in a computer simulation of the spectra.  Since the hyperfine coupling that makes up the
appearance of an ESR spectrum is determined by the atoms adjacent to the radical, it
would be possible to simulate the spectra of AD with DMPO in chloroform and gain
insight into the structure of the parent radical being trapped.  This was not done in these
studies, however, due to the lack of access of such capabilities.
Autoquenching of hydroxyl radical was explored by analyzing the hydroxyl-
DMPO signal from increasing concentrations of AD.  While the peak appeared to be
reached around 12 mg/mL AD, further studies could not be completed due to a
crosslinking or solidifying of the AD solution.  This may indicate that AD is both a free-
radical producer and scavenger on different parts of its structure.  When one AD
molecule is in the form of a radical, another may adduct with it, eliminating the radical
signal.  However, the importance of this characteristic in vivo is not clear. AD is
accumulated to a high degree in lung cells and tissues, and autoquenching could explain
why the cells are not damaged by radical production (if any occurs).  This could help
explain why animals treated with oral AD accumulate large amounts of drug without
cellular activation.  However, no evidence for an AD complex (i.e. an AD dimer, etc.)
was found during HPLC analysis of AD levels in animals treated with oral AD.
Attempts to examine free radical production in vivo were unsuccessful.  DMPO
was instilled with AD into rats, and then withdrawn, but even the expected baseline
hydroxyl-DMPO signal was absent.  Protocols involving the treatment of excised lungs,
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lung homogenates, and varying concentrations of BAL cells failed to yield any radical
signals.  This obviously could mean that radicals are not involved in the AD-induced
damage.  However, it is possible that the activated DMPO was actually quenched by
endogenous and cellular antioxidants.  Experiments with cells and tissues have to be
carefully balanced to avoid the quenching of the spin trap while maintaining enough cells
to affect.  Therefore all experiments with animals, tissues, and cells were inconclusive.
To determine if an aryl radical could be formed and measured in AD solution
(3.125 mg/mL) in water with DMPO, AD solution was analyzed with and without UV
treatment.  UV exposure for the first 10 min of the 30 min incubation produced a typical
aryl-DMPO signal split with a hydroxyl-DMPO signal.  Therefore it is possible for an
aryl radical to be formed in AD solution.  However, the importance of the aryl radical in
the non-UV treated samples was not clear.  It is possible that the hydroxyl signal was
produced by a small amount of aryl radical in solution, or that a non-aryl radical pathway
of AD-induced free radical production was occurring.
To determine if the hydroxyl signal could be eliminated, several antioxidants and
combinations of antioxidants were tested in AD solution (3.125 mg/mL; 4.5 mM) with
DMPO.  While several antioxidants had varying effectiveness in eliminating the hydroxyl
signal, a combination of Trolox (45 mM) and ascorbate (22.5 mM) completely inhibited
the hydroxyl signal.  This combination was chosen for an attempt to protect animals from
i.t. AD-induced damage at 15 min.  For the protection experiment, the antioxidants had to
be at least partly water-soluble, as they would need to be in solution with AD to ensure
equal distribution with the drug.   However, if the drug partitioned into the lipid
membrane, any protective effect of the water-soluble antioxidants could be lost.  Trolox
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is a water-soluble vitamin E derivative, and was chosen in an attempt to protect the lipid
compartment.  Ascorbate was chosen to protect the aqueous compartment, partly because
of its ability to interact with vitamin E in other situations to scavenge radicals.  However,
the presence of these antioxidants in solution actually exacerbated the damage at 15 min.
Effects were both qualitative (physical examination revealed worse hemorrhaging of the
lungs and a greater amount of blood in the BAL fluid) and quantitative, as evidenced by
increased albumin in the BAL fluid from animals given AD and antioxidants, as
compared to animals given AD alone.  Curiously the added apparent damage did not
increase LDH activity in the BAL fluid of rats receiving AD with antioxidants.  This
could be due to the nature of the alveolar-capillary barrier.  Type I epithelial cells that
form this barrier are extremely thin, with little cytoplasm but a large surface area.
Damage done to this region on the lungs may result in a greater leakage of albumin to the
airways without significantly increasing the level of LDH in the BAL fluid due to the
limited amount of cytoplasm of type I cells.  It is possible that significantly more damage
can be done to the alveolar-capillary barrier without a significant increase in cell death, if
that cell death is occurring in the alveoli.  Antioxidant solution alone had no effect on
albumin or LDH activity in the first BAL fraction at 15 min as compared to sterile water.
The lack of protection by antioxidants from i.t. AD-induced damage does not
resolve the issue of the involvement of free radicals in the damage.  It could be possible
that AD is causing damage through a non-radical pathway, and the radicals signals
observed with ESR are incidental, caused by low-level deiodination and radical
formation, but not to a level that induces damage.  Or it is possible that the water-soluble
antioxidants chosen could not protect cells from AD-radical induced damage in the lipid
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compartment.  Other possibilities for AD-induced damage that do not involve radicals do
exist.  While AD is a hydrochloride, the effect is mostly likely not due to the pH of the
AD solution.  Because of its amphiphilic structure, AD could simply be acting as a
detergent, and as such could permeabilize cell membranes upon contact.  Even though
AD is instilled in solution, it could also have the effects of a particulate if it does not
remain in solution in the fluid lining of the lungs.  AD precipitating adjacent to cell
membranes may have a damaging effect on those membranes.  Further studies would be
needed to control for each of these possibilities to determine the most likely mechanism
for AD-induced damage.  However, since the damage that occurs is not similar to the
pathology of AIPT in human patients, there would be little clinical relevance of those
studies.  The role of direct cytotoxicity of AD in human AIPT has not been completely
elucidated.  The finding of elevated LDH activity in the serum of a patient with AIPT
(Drent et al., 1998) could be attributed to AD-induced cytotoxicity, or cytotoxicity
accompanying the acute inflammatory reaction.
To examine if deiodination of AD occurred when dissolved in water, solutions of
AD dissolved in water and methanol were analyzed with electrospray mass spectroscopy
with Robert Smith (Dept of Biochemistry, WVU).  Intact AD was expected to have a
molecular weight of ~645 Da.  Instead, AD was found at 651, 652, and 653 Da.
Electrospray analysis usually adds 1.0 Da to the molecular weight. This means that the
AD in both methanol and water was either fully saturated with hydrogen, the technique
added more than 1 Da to the apparent molecular weight, or that this particular AD has an
unusual amount of 13C in its structure.  Whatever caused the discrepancy, conclusions can
still be drawn from this experiment.  No evidence was found for deiodinated AD, either
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mono (~518 Da) or di-deiodinated (~393 Da) in the positive ion spectra from AD in
methanol.  However, possible di-deiodinated AD (~393 Da) was found in the AD-water
solution.  No evidence was found for a mono-deiodinated compound that would have
been expected to be present as well in the solution, possibly in higher concentrations than
the di-deiodinated compound.  Also, no evidence for free iodine in solution (I-, I2, or I3;
~127, ~254, and ~381 Da respectively) `was found in the negative ion spectra for AD in
methanol or water.  The peaks at 167.8 and 212.6 Da in both negative-ion spectra are
known contaminants of the analysis system.  Thus the ~393 Da peak could represent di-
deiodinated AD, although no iodine or mono-deiodinated AD were found, or an unknown
AD breakdown product, implying that dissolving AD in water may indeed change its
structure.  No evidence for this breakdown product was found utilizing HPLC analysis
with a spectrometer, but the product might not absorb at the UV wavelength used to
detect AD, especially if it was not di-deiodinated AD, which would have maintained its
ring structure.  The overall conclusions of the mass spectroscopy is that AD does not
significantly deiodinate when dissolved in water, but may change structurally in some
other undetermined fashion. This could imply that AD is able to generate free radicals in
an as of a yet-undetermined mechanism, or it could mean that that the levels of mono-
deiodination in solution are so small as to be undetectable by mass spectroscopic
analysis, but enough to produce radical signals in ESR analysis.  This latter scenario
seems unlikely given the relatively greater sensitivity of mass spec vs. the relatively less-
sensitive technique of ESR spin trapping.  1H-Nuclear magnetic resonance analysis of the
dry AD powder confirmed the expected structure of AD, which does not yield any insight
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into what may have caused the carbon-based radical signal detected by ESR in the dry
powder.  Thus the mechanism for free radical production by AD remains unclear.
Intratracheal AD administration leads to a massive damage to the lungs within the
first 15 min.  This damage involves the death of airway and parenchymal cells, and
results in leakage of albumin through the alveolar-capillary barrier as well as release of
intracellular LDH.  This damage seems to be a result of some aspect of the drug itself.  At
least a portion of the drug was found to be both a radical and capable of producing
radicals in solution.  The role of these radicals in the damage caused by i.t. AD remains
unclear.  The drug does not appear to undergo deiodination in solution, leaving the
question of the exact mechanism of AD radical production unanswered.  An undescribed
mechanism of radical production from AD could be involved.
Because of the damage that i.t. AD causes soon after administration, this
technique is not a relevant method to model human AIPT.  If studies of AIPT are to
continue, another animal model of the toxicity needs to be developed, one that hopefully
employs an oral or i.v. route of administration.  While rodents have been resistant to
AIPT development when dosed orally, the search for another model can be expanded into
other species.  Even though the expense and technical considerations are greater for non-
rodent species, including primates, the continued increase of the use of AD justifies those
measures.
While modeling AIPT with intratracheal AD administration is not clinically
relevant, some findings with this model warrant further consideration.  The use of SP-D
as a biomarker deserves further investigation.  Even though the damage to the alveolar-
capillary barrier induced by AD in this model could have allowed SP-D into the serum,
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the successful use of this protein as a biomarker for other human lung toxicities warrants
clinical trials in human patients.  A biomarker could aid in the early diagnosis of AIPT
and result in treatment of the condition rather than further development that could lead to
death.  The role of cytotoxicity in human AIPT also needs to be further explored.  The
large amount of cytotoxicity from relatively low drug levels begs the question of the
effects of AD in the much higher concentrations seen in the lung in vivo.  Finally, the
ability of AD to readily generate radicals in solution is an important finding.  Because the
mechanism of AD radical generation may not be as hypothesized in the literature, the
mechanism of free radical production without AD deiodination needs to be explored. The
possibility of radical formation has implications for some of the side effects seen with
AD treatment in patients.  Skin photosensitivity could be due in part to the direct
activation by sunlight of the drug stored in skin and subcutaneous tissues, leading to
radical formation and skin damage.  The accumulation of AD in the cornea could lead to
activation that causes the oxidation of proteins there, causing opacity and inflammation.
It is clear that stored AD in other tissues does not regularly undergo deiodination and
activation induced by UV light, but these studies suggest that deiodination may not be
necessary for radical production.  It is therefore possible that in at least some cases of
human AIPT, low levels of radical formation by non-bound drug in lung tissue could
cause damage and lead to the persistent inflammation observed.  Also, any proteins
modified by radical damage or AD-hapten formation could then be seen as foreign and
initiate the immune response seen in some individuals. As other cationic amphiphilic
drugs are known to cause phospholipidosis without the widespread reports of
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inflammation and fibrosis as with AIPT, it is possible that radical formation is unique to
AD and possibly involved it the more damaging aspects of the toxicity.
It is hoped that these studies will contribute to the eventual determination of the
mechanisms involved in AIPT development, if by nothing else sparing further study on
animal models involving i.t. AD administration.
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